WO2015165480A1 - Compositions de vaccin de cytomégalovirus humain et leur procédé de production - Google Patents

Compositions de vaccin de cytomégalovirus humain et leur procédé de production Download PDF

Info

Publication number
WO2015165480A1
WO2015165480A1 PCT/EP2014/001168 EP2014001168W WO2015165480A1 WO 2015165480 A1 WO2015165480 A1 WO 2015165480A1 EP 2014001168 W EP2014001168 W EP 2014001168W WO 2015165480 A1 WO2015165480 A1 WO 2015165480A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
sequence variants
sequence
vector
inventive
Prior art date
Application number
PCT/EP2014/001168
Other languages
English (en)
Inventor
Antonio Lanzavecchia
Laurent Perez
Original Assignee
Institute For Research In Biomedicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institute For Research In Biomedicine filed Critical Institute For Research In Biomedicine
Priority to PCT/EP2014/001168 priority Critical patent/WO2015165480A1/fr
Priority to PCT/EP2015/000843 priority patent/WO2015161926A1/fr
Priority to AU2015251221A priority patent/AU2015251221A1/en
Priority to CA2944230A priority patent/CA2944230A1/fr
Priority to US15/305,494 priority patent/US20170119874A1/en
Priority to EP15719409.3A priority patent/EP3134117A1/fr
Publication of WO2015165480A1 publication Critical patent/WO2015165480A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron

Definitions

  • the present invention relates to the field of HCMV vaccination, in particular to vaccine compositions for use in the vaccination against human cytomegalovirus, methods of producing the same as well as to methods of vaccination.
  • HCMV Human Cytomegalovirus
  • the virus spreads via excretion in nearly all body fluids, such as urine, saliva, vaginal secretions, semen or breast milk. Especially infants and toddlers shed high amounts of virus for months or even years and represent a substantial risk for transmitting the virus to pregnant women by saliva or urine. Sexual transmission of the virus is a common way of infection in adults.
  • HCMV represents a major threat for the developing fetus and immunocompromised patients.
  • solid organ transplants SOT
  • HSCT hematopoietic stem cell transplant
  • Infections can occur as newly acquired infection, which is frequently observed in HCMV seronegative recipients receiving SOT from seropositive donors, or as re-current infection due to reactivation of latent virus in seropositive recipients.
  • HCMV infection and CMV-induced damage in the fetus may also cause spontaneous abortion or prematurity.
  • Organ damage is thought to be caused by HCMV replication in target organs like the central nervous system of the foetus and indirectly by HCMV-induced placental dysfunction. Permanent impairments mostly affect the central nervous system and include progressive hearing loss, spastic tetraplegia, mental retardation and visual impairments (Watemberg et al. Clin Pediatr (Phi la). 2002;41 (7):51 9-22).
  • HCMVHIG HCMV hyperimmune human IgG
  • Wi ld-type HCMV as a prototype-member of the ⁇ -herpesvirus family possess a double-stranded DNA (dsDNA) genome of around 235 kb, which is longer than all other human herpesviruses and one of the longest genomes of al l human viruses in general . It is estimated that the HCMV genome codes for more than 1 65 open reading frames (ORFs).
  • the mature virions are about 200nm in diameter and are comprised of more than 50 viral proteins, including viral capsid proteins, tegument proteins and envelope glycoproteins.
  • the HCMV genome has the characteristic herpesvirus class E genome architecture, consisting of two unique regions (unique long UL and unique short US), both flanked by a pair of inverted repeats (terminal/internal repeat long TRL/IRL and internal/terminal repeat short IRS/TRS). Both sets of repeats share a region of a few hundred baise pairs (bps), the so-called "a” sequence ; the other regions of the repeats are sometimes referred to as "b” sequence and "c” sequence .
  • the genome exists as an equimolar mixture of four genomic isomers by inversion of UL and US regions (Murphy et al. Curr. Top. Microbiol. Immunol. 2008, 325, 1-1 9).
  • the first complete HCMV genome of the CMV strain AD1 69 was published in 1990 and was the largest contiguous sequence generated by M13 shotgun cloning and Sanger sequencing at the time. Of the more than 1 65 genes encoded by HCMV, less than one-fourth are essential for viral replication and are conserved across herpesvirus families.
  • the gene products ORFs 37-60 are e.g. detected following in vitro infection of CD34+ primary hematopoietic progenitor cells (HPCs) or myeloid lineage cells and cell line models.
  • HPCs primary hematopoietic progenitor cells
  • Some viral glycoproteins such as gM, gN and gB are used by HCMV to infect different cell types, while glycoprotein complexes containing gH and gL mediate cell type-specific virus entry.
  • a pentameric complex comprising gH, gL, pUL128, pUL130 and pUL1 31 (also referred to as gHgLpUL128L) was shown to be required for infection of endothelial, epithelial and myeloid cells by clinical HCMV isolates.
  • In vitro cultured viruses with mutations in the UL128-1 31 locus have lost tropism for endothelial and epithelial cells, but have retained the expression of the gHgL dimer, which is sufficient to infect fibroblasts.
  • MMV approaches taken include live attenuated Towne and AD1 69 viruses, Towne/Toledo chimeric viruses and dense body (DB) vaccines (cf. Fu, TM et al., Vaccine 2014, May 7;32(22):2525-2533).
  • HCMV live-virus approach including atherosclerosis, immune senescence, reactivation from latency and potentially even Alzheimer's disease have rendered this approach unattractive for the development of a HCMV vaccine (Schleiss, Future Virol . 201 3, 8(12):1 1 61 - 1 1 82).
  • the IAV approach is designed to present defined one or more viral antigens, which may be delivered in form of recombinant protein, a DNA vaccine or viral vector.
  • Antigens which are typically considered for the IAV approach comprise antigens that are recognized by the dominant humoral or T-cell response, or both, in natural ly infected humans. For example, attempts have been made in developing a subunit vaccine based on glycoprotein B (gB), which is an abundant surface glycoprotein of HCMV involved in virus fusion and a target of neutralizi ng antibodies (nAbs): gB has been shown to elicit T cell and antibody response and it represents the basis of most vaccines developed so far.
  • glycoprotein B glycoprotein B
  • nAbs neutralizi ng antibodies
  • a MF59-adjuvanted gB vaccine showed modest efficacy in preventing infection of seronegative women and only reduced duration of viremia in transplant recipients.
  • the gB vaccine used was produced recombinantly, differing from the natural gB glycoprotein, which is membrane-anchored and composed of two subunits linked by disulfide bonds, i n that the recombinant molecule was designed as a single molecule with its furin cleavage site mutated and its transmembrane domain deleted.
  • the soluble gB vaccine is not designed to assemble into a trimeric complex as has been described for the gB of herpes simplex virus-1 (Heldwein et al., Science 2006; 31 3 :21 7-20). It is therefore unlikely that the recombinant gB vacci ne presents with the antigenic structure of that of the wild-type gB glycoprotein i n the viral envelope. This altered antigenic structure may explain the fi nding that most of the antibodies i nduced by the vaccines lacked vi rus neutralizing activity, whi le those neutralizing did not block efficiently i nfection of epithel ial cel ls.
  • IAV vaccines have raised the question whether vaccine-i nduced antibody responses raised against a single viral glycoprotein would be sufficient to induce an antibody response resembling that of natural HCMV infection, in particular with regard to the number of neutralizing antibodies.
  • the immunological goal is to identify the best target of neutralizing antibodies in natural HCMV infection or a crucial component of such immunity in order to produce a vaccine that induce a neutralizing antibody response equal or even better than that induced by HCMV infection.
  • limitations are imposed by the extent of how accurately or faithfully human immune responses can be characterized by in vitro or animal models: Many variables in the immune assays including HCMV strains used can lead to contradictory or even misleading results, such as the recent findings of epithelial tropism-deficiency of the AD1 69 HCMV laboratory strains, which have been widely used for vaccine development.
  • HCMV-specific immunogens including recombinant proteins, virions, dense bodies have all been evaluated for immunogenicity in a number of animals, including mice, rabbits, hamsters, guinea pigs and rhesus macaques, however, these studies do not allow to evaluate efficacy of the different immunogens as vaccines, as HCMV wil l not replicate in these model organism or cause disease.
  • HCMV vaccine composition which is capable of eliciting an immune response resulting in the formation of a repertoire of neutralizing antibodies that are protective against infection of all cellular targets while minimizing production of non-neutralizing antibodies, i.e. capable of inducing an antibody response of high "specific activity".
  • vaccine compositions which comprise the pentameric glycoprotein complex of the HCMV proteins gH, gL, UL128, UL1 30 and UL1 31 as immunogenic components, result in the formation of a high number of neutralizing antibodies against HCMV and thus may provide an efficient vaccine against HCMV infection. More specifically, the inventors have surprisingly found that a vector comprising nucleotide sequences encoding each of the five subunits of this HCMV pentameric glycoprotein complex, i.e.
  • gH, gL, UL128, UL130 and UL1 31 (also referred to as "immunogenic components" in the following), enables the preparation of a vaccine, which elicits the formation of high numbers of predominantly neutralizing antibodies against HCMV infection of fibroblasts, epithelial, endothelial and myeloid cells.
  • a vector comprising nucleotide sequences encoding each of the five subunits of the HCMV pentameric glycoprotein complex, i.e.
  • a vaccine according to the present invention which is obtainable by the inventive vector, shows a higher specific activity compared to conventional vaccines against HCMV infection.
  • the present invention thus provides for a vector which comprises a transcription system, comprising one or more promoter(s), preferably one or two promoter(s) (which are typically operable in the mammalian cell), which is/are operably linked to one or more open reading frames coding for the above mentioned immunogenic components gH, gL, UL1 28, UL130 and UL131 .
  • a single vector encodes all five immunogenic components gH, gL, UL128, UL130 and UL1 31 , preferably each of them in a single copy.
  • the transcription system of the inventive vector comprises the five immunogenic components gH, gL, UL128, UL1 30 and UL131 arranged in one or more open reading frames (ORF) whereby usually a promoter is operably linked to each of the at least one open reading frames.
  • ORF open reading frames
  • the inventive vector is usually used for the preparation of a vaccine for use in mammals, in particular in humans, the vector is in general designed for this use.
  • the vector is preferably suitable for expressing HCMV glycoproteins in a mammalian cell and used in this context, since vaccine preparations are advantageously based on a mammalian expression system for safety aspects including e.g. the provision of an appropriate glycosylation pattern.
  • the HCMV pentameric glycoprotein complex which is obtainable by the inventive vector, is secreted, i.e. released from the cells expressing it into the supernatant.
  • the transmembrane domain of the gH subunit is preferably mutated, in particular deleted, e.g. SEQ ID:NOs 21 and 35 or sequence variants thereof.
  • sequence encoding gH (or an amino acid sequence for gH) relates preferably to such gH sequences, wherein the transmembrane domain is mutated, preferably deleted.
  • the at least one promoter of the inventive vector of the inventive gene expression system may be chosen from any appropriate promoter, in particular any viral promoter and, further, any promoter of herpes virus origin. If more than one promoter is present in the inventive vector, the further promoter of the inventive vector of the inventive gene expression system may be the same as or different from the first promoter. More preferably, the first promoter may be selected from the group consisting of a MCMV, a HCMV, a SV40, a HSV-TK, an EF1 -1 a and PGK promoter. Accordingly, any further promoter may be selected from the group consisting of a MCMV, a HCMV, a SV40, a HSV-TK, an EF1 -1 a and PGK promoter as well.
  • the inventive vector of the inventive gene expression system comprises by its transcription system nucleotide sequences coding for all above mentioned immunogenic components, preferably as defined by SEQ ID Nos: 3 (UL128), 7 (UL130), 1 1 (UL1 31 ), 21 (gH) and 25 (gL) or sequence variants thereof, which are arranged in at least one open reading frame and whereby a promoter is operably linked to preferably each open reading frame .
  • the at least one open reading frame comprising at least one nucleotide sequence selected from the group consisting of nucleotide sequences encoding an amino acid sequence for gH, gL, UL128, UL1 30, and UL1 31 , in particular according to SEQ ID NO:21 , SEQ ID NO:25, SEQ ID NO:3, SEQ ID NO:7 and SEQ ID NO:l 1 or sequence variants thereof, whereby the vector comprises each of the nucleotide sequences selected from the group consisting of nucleotide sequences encoding an amino acid sequence for gH, gL, UL128, UL1 30, and UL131 , in particular according to SEQ ID NO:21 , SEQ ID NO:25, SEQ ID NO:3, SEQ ID NO:7 and SEQ ID NO:1 1 in at least one open reading frame linked to at least one promoter.
  • nucleotide sequences encoding gH, gL, UL1 28, UL130 and UL1 31 are preferably the nucleotide sequences encoding the amino acid sequences according to SEQ ID NO:21 , SEQ ID NO:25, SEQ ID NO:3, SEQ ID NO:7 and SEQ ID NO:1 1 or sequence variants thereof.
  • nucleotide sequences encoding the amino acid sequences according to SEQ ID NO:21 , SEQ ID NO:25, SEQ ID NO:3, SEQ ID NO:7 and SEQ ID NO:1 1 are the nucleotide sequences according to SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:4, SEQ ID NO:8 and SEQ ID NO:12 or sequence variants thereof.
  • sequence variants of gL and gH are e.g. SEQ ID NO:35, SEQ ID NO:37, while sequence variants of pUL130, pUL131 are e.g. SEQ ID NO:31 and SEQ ID NO:33.
  • Any order for an arrangement of the nucleotide sequences coding for the above defined immunogenic components may be chosen as long as nucleotide sequences encoding each of the immunogenic components gH, gL, UL128, UL130 and UL1 31 are contained, preferably as a single copy, in a single vector.
  • the arrangement is such that the nucleotide sequences coding for gH and gL are located adjacent to each other and/or the nucleotide sequences coding for UL128, UL130, and UL131 are located adjacent to each other. More preferably, the arrangement of the nucleotide sequences coding for UL128, UL1 30 and UL131 within the open reading frame is chosen such that they are located in the above order in 5'-3' direction.
  • the inventive vector comprises by its transcription system one single open reading frame comprising nucleotide sequences which code for all of the immunogenic components gH, gL, UL128, UL130 and UL131 , preferably each in a single copy.
  • the nucleotide sequences encode amino acid sequences according to SEQ ID No: 3, 7, 1 1 , 21 and 25 or sequence variants thereof.
  • one promoter is operably linked to this one open reading frame.
  • the inventive vector comprises by its transcription system more than one promoter operably linked to more than one open reading frame comprising nucleotide sequences which code for the immunogenic components gH, gL, UL128, UL130 and UL1 31 , preferably according to SEQ ID No: 3, 7, 1 1 , 21 and 25 or sequence variants thereof.
  • the immunogenic components encoded by the underlying nucleotide sequences e.g.
  • SEQ ID NOs: 4 (UL128), 8 (UL1 30), 12 (UL131 ), 22 (gH) , and 26 (gL) or other nucleotide sequences coding for gH, gL, UL128, UL1 30 and UL1 31 may be allocated in any possible arrangement (and any order) to 2 to 5 open reading frames (each open reading frames operatively linked to a promoter), i.e.
  • two open reading frames are provided by the inventive vector of the inventive gene expression system, one of them comprising the nucleotide sequences encoding two of the above five immunogenic components according to SEQ ID NOs 3, 7, 1 1 , 21 , and 25, while the other open reading frame encodes for the other three immunogenic components.
  • the transcription system preferably comprises (a)(i) a first promoter operable in a mammalian cell operably linked to (a)(ii) a first open reading frame (ORF), which comprises a nucleotide sequence, which preferably encodes SEQ ID NO:21 and SEQ ID NO:25 or sequence variants thereof, (b)(i) a second promoter operable in said mammalian cell and operably linked to b(ii) a second open reading frame (ORF), which comprises a nucleotide sequence preferably encoding SEQ ID NO:3, SEQ ID NO:7 and SEQ ID NO:1 1 or sequence variants thereof.
  • ORF open reading frame
  • the first open reading frame may encode one of SEQ ID NOs 3, 7 or 1 1 or sequence variants thereof and, both, SEQ ID NOs 21 and 25 or sequence variants thereof, while the second open reading frame encodes SEQ ID NOs 3 and 7 or sequence variants thereof or 3 and 1 1 or sequence variants thereof or 7 and 1 1 or sequence variants thereof, respectively.
  • the nucleotide sequences encoding the five immunogenic components gH, gL, UL128, UL1 30 and UL1 31 may be also arranged in any other way in the two open reading frames, e.g.
  • ORF comprising a nucleotide sequence encoding gH, gL and one of UL128, UL1 30 and UL1 31 and a second ORF comprising a nucleotide sequence encoding the other two of UL128, UL1 30 and UL131 .
  • the inventive vector preferably comprises at least two transcription units, each of which comprises an ORF, operably linked to a promoter.
  • Each of the ORFs may further comprise e.g. a 5' start codon and may encode two or more HCMV viral glycoproteins, such as e.g. gH (e.g. SEQ ID NO: 21 ), gL (e.g. SEQ ID NO:25), pUL128 (e.g. SEQ ID NO:3), pUL1 30 ( e.g. SEQ ID NO:7), or pUL1 31 (e.g. SEQ ID NO: 1 1 ), or sequence variants thereof.
  • gH e.g. SEQ ID NO: 21
  • gL e.g. SEQ ID NO:25
  • pUL128 e.g. SEQ ID NO:3
  • pUL1 30 e.g. SEQ ID NO:7
  • pUL1 31 e.g. SEQ ID NO: 1 1
  • the inventive vector may also encode one or more immunogenic component(s) other than those mentioned above.
  • the inventive vector preferably in an inventive gene expression system, may also comprise nucleotide sequences encoding one or more of the following further functional components: signal peptide sequence(s), linking sequence(s), tag sequence(s), sequences comprising a cleavage site and sequences comprising sites for ribosomal skipping.
  • the first and/or the second ORF of the vector of the inventive expression system may further comprise one or more a nucleotide sequences encoding amino acid sequences, which reflect ribosomal skipping sites.
  • ribosomal skipping sites are located in between nucleotide sequences encoding for the immunogenic components such that the immunogenic components are provided as separate entities in the course of mRNA translation.
  • the underlying mechanism is based on non-formation of a covalent linkage between two amino acids, i.e. G (Gly) and P (Pro) during mRNA translation.
  • the mRNA translation is not interrupted by the non-formation of a covalent bond between the Gly/Pro, but rather proceeds without stopping the ribosomal activity on the mRNA.
  • the ribosomes do not form a peptide bond between these amino acids, if a sequence pattern Asp- Val/lle-Glu-X-Asn-Pro-Gly ⁇ Pro occurs in a peptide sequence.
  • Non-formation of a covalent bond occurs between the C-terminal Gly-Pro position of the above amino acid stretch.
  • the vector of the present invention preferably provides for such a self-processing sequence by preferably locating a nucleotide sequence encoding for the above sequence motif between at least two of the nucleotide sequences encoding for an immunogenic component as defined above, preferably the underlying nucleotide sequence of the first and/or second open reading frame encodes for such a self-processing peptide between all of the immunogenic components as defined above.
  • a self-processing sequence motif it becomes possible to provide one open reading frame containing two or more nucleotide sequences encoding for an immunogenic component as defined above, allowing, however, to still produce separate entities of the immunogenic components as the result of mRNA-translation.
  • the invention allows to ensure strict compliance with a 1 :1 :1 :1 :1 stochiometry and is not dependent on the less precise (in terms of the intracellular ratio of the immunogenic components) production of immunogenic components resulting from polycistronic gene products, which dependent on the activity of the ribosomes on ribosomal entry site (IRES).
  • the inventive vector may comprise a nucleotide sequence encoding SEQ ID NO:5 (T2A) and SEQ ID NO:9 (F2A), SEQ ID No: 23 (P2A) (or e.g. its variants SEQ ID No: 27 or 29) or sequence variants thereof.
  • SEQ ID NO: 5 and SEQ ID NO: 9 are encoded by nucleotide sequences SEQ ID Nos 6 and 10, SEQ ID No 23, 27 and 29 are encoded by SEQ ID No. 24, 28 and 30 or sequence variants thereof. They all reflect self-processing peptides T2A, F2A and P2A, respectively, of the Foot-and-Mouth Disease virus.
  • the nucleotide sequences according to SEQ ID No 6 and 10 are located in between the nucleotide sequences coding for the immunogenic components, in particular in between UL128 and UL130 and/or in between UL130 and UL 131 .
  • the nucleotide sequence encoding SEQ ID No 23 are preferably located between the nucleotide sequence between gH and gL provided e.g. by another open reading frame. In any case, each of these self- processing nucleotide sequences may be positioned between any of the nucleotide sequences of the immunogenic components.
  • the inventive vector of the inventive gene expression system comprises a first and/or second ORF, which comprise at least one or more nucleotide sequences selected from the group comprising SEQ ID NO:6 and/or SEQ ID NO:10 and/or SEQ ID NO:24 and/or SEQ ID NO:28 and/or SEQ ID NO:30 or sequence variants thereof.
  • the inventive vector of the inventive gene expression system comprises a first ORF, which comprises at least one nucleic acid sequence according to SEQ ID NO:24 and/or SEQ ID NO:28 and/or SEQ ID NO:30 or sequence variants thereof and the second ORF comprises at least one nucleotide sequence according to SEQ ID No: 6 and/or 10 or sequence variants thereof.
  • the inventive vector may comprise one or more additional nucleotide sequences, which encodes a signal peptide, in particular a signal peptide, which allows the peptides to produced in the mammalian cell to be secreted to the extracellular environment for a ready-to-go protein complex harvesting process.
  • signal peptides IgG signal peptide sequences, e.g. a human or murine IgG signal peptide, such as e.g. SEQ ID NO:19 may be used.
  • the sequence encoding the gH signal peptide is replaced by a sequence encoding the IgG leader sequence, e.g.
  • the underlying nucleotide sequences encoding such signal peptide sequences may be located such that each immunogenic component, if translated as a separate entity, e.g. due to the incorporation of self-processing ribosomal skipping sites in the open reading frame's nucleotide sequence encompasses such a signal peptide sequence.
  • the signal peptide is preferably identical for each immunogenic component and preferably identically located, e.g.
  • inventive vector may further comprise one or more nucleotide sequences coding for one or more tag peptide(s), cleavage sites and/or linker peptides.
  • tag, cleavage site or linker peptide encoding nucleotide sequences may be positioned within the first and/or second ORF. They may be selected from e.g.
  • SEQ ID NO:14 SEQ ID NO:1 6, SEQ ID NO:1 8 and/or SEQ ID NO: 42 or sequence variants thereof encoding SEQ ID NO:1 3, SEQ ID NO:15, SEQ ID NO:1 7 and SEQ ID NO:41 or sequence variants thereof.
  • They exhibit a TEV cleavage site, a GS linker, a STREP-tag and a 6xHis-tag, which may e.g. be used for purification of encoded HCMV surface glycoproteins and/or of the inventive soluble protein complex.
  • Nucleotide sequences encoding cleavage sites may incorporated into the open reading frame to e.g. avoid the use of self-processing skipping sites. Such cleavage sites allow to - postranslationally - cleave the protein translated from the one or more open reading frames, in particular a protein, which comprising two or more of the immunogenic components.
  • a protein cleavage e.g. by a peptidase or proteinase
  • the covalently linked immunogenic components comprised in the translated gene product is processed into fragments, each fragment preferably comprising one immunogenic component. Accordingly, such cleavage sites are positioned within linker sequences between the immunogenic components.
  • cleavage sites are based on its use to specifically cleave the peptide products obtained e.g. due to ribosomal skipping such that any N- or C-terminal elongation of the immunogenic component (resulting from mRNA-translation) is cleaved off, e.g. any amino acids elongating the immunogenic component, e.g. at its C-terminus, due to the ribosomal skipping site motif.
  • the cleavage site is preferably located adjacent to a tag, which is useful for the purification such as a 6xHis-tag, so that the tag can be removed after purification and is thus not present in the final product to be used for vaccination. Under such circumstances, the cleavage site is preferably located close to or directly linked to the N- or C-terminal residue of the immunogenic component.
  • Another embodiment of the present invention provides a vector, which does not contain - between immunogenic components - any skipping or cleavage sites.
  • the nucleotide sequence of the open reading frame provides one single protein chain comprising more than immunogenic component, e.g. 2 to 5 immunogenic components as defined above, which are covalently connected, preferably via a linker chain.
  • the complex of the invention resulting from an aggregation of each of the immunogenic components may thereby be formed by at least two (or even 5) immunogenic components, which are all covalently linked with each other.
  • the inventive vector comprises a first ORF, which comprises the first promoter and operably linked to it nucleotide sequences encoding the amino acid sequence of SEQ ID NO:1 9, SEQ ID NO:21 , SEQ ID NO:23 and SEQ ID NO:25 or sequence variants thereof, or the nucleotide sequences encoding the amino acid sequences of SEQ ID NO:1 9, SEQ ID NO:35, SEQ ID NO:27 and SEQ ID NO:37 or sequence variants thereof, or the nucleic acid sequences encoding the amino acid sequences of SEQ ID NO:1 9, SEQ ID NO:35, SEQ ID NO:29 and SEQ ID NO:7 or sequence variants thereof, and a second ORF, which comprises a second promoter and, operably linked to it, nucleotide sequences encoding amino acid sequences according to SEQ ID NO:1 , SEQ ID NO:3, SEQ ID NO:23, SEQ ID NO:7, SEQ ID NO:23,
  • the inventive vector may comprise additional sequences such as e.g. the nucleotide sequence encoding SEQ ID NO:1 , which reflects the amino acid sequence of a viral signal peptide, or e.g. the vector of the inventive gene expression system may comprise in a second ORF sequence variants of, pUL130, pUL131 , such as e.g. the nucleotide sequences encoding SEQ ID NO:31 and/ or SEQ ID NO:33, SEQ ID NO:37, which may be present in any order as described below, with the exception of SEQ ID NO:1 9.
  • additional sequences such as e.g. the nucleotide sequence encoding SEQ ID NO:1 , which reflects the amino acid sequence of a viral signal peptide
  • the vector of the inventive gene expression system may comprise in a second ORF sequence variants of, pUL130, pUL131 , such as e.g. the nucleotide sequences encoding SEQ ID NO:31 and
  • the vector of the inventive gene expression system comprises a second ORF, which comprises operably linked the nucleic acid sequences encoding SEQ ID NO:1 , SEQ ID NO:3, SEQ ID NO:23, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:1 1 , SEQ ID NO:1 3, SEQ ID NO:1 5 and SEQ ID NO:1 7, or the nucleic acid sequences encoding SEQ ID NO:1 9, SEQ ID NO:3, SEQ ID NO:27, SEQ ID NO:31 , SEQ ID NO:27 and SEQ ID NO:33, or the nucleic acid sequences encoding SEQ ID NO:1 9, SEQ ID NO:3, SEQ ID NO:29, SEQ ID NO:31 , SEQ ID NO:29 and SEQ ID NO:33, or the nucleic acid sequences encoding SEQ ID NO:1 9, SEQ ID NO:3, SEQ ID NO:27, SEQ ID NO:31 , SEQ ID NO:27 , SEQ ID NO:
  • the inventive vector comprises a second ORF, which comprises a nucleotide sequence encoding SEQ ID NO:3, SEQ ID NO:7, and SEQ ID NO:1 1 or sequence variants thereof.
  • the first ORF and/or second ORF of the inventive vector comprise the nucleotide sequences encoding SEQ ID NO:1 9, SEQ ID NO:3, SEQ ID NO:27, SEQ ID NO:31 , SEQ ID NO:27, SEQ ID NO:33, SEQ ID NO:1 9, SEQ ID NO:35, SEQ ID NO:27 and SEQ ID NO:37 or sequence variants thereof.
  • the first ORF and/or second ORF of the inventive vector comprises the nucleotide sequences encoding SEQ ID NO:1 9, SEQ ID NO:3, SEQ ID NO:29, SEQ ID NO:31 , SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:1 9, SEQ ID NO:35, SEQ ID NO:29 and SEQ ID NO:37 or sequence variants thereof.
  • the first ORF and/or second ORF of the inventive vector comprise the nucleotide sequences encoding SEQ ID NO:19, SEQ ID NO:3, SEQ ID NO:27, SEQ ID NO:31 , SEQ ID NO:27, SEQ ID NO:33, SEQ ID NO:13, SEQ ID NO:1 5, SEQ ID NO:39, SEQ ID NO:1 9, SEQ ID NO:35, SEQ ID NO:27 and SEQ ID NO:37 or sequence variants thereof.
  • the first ORF and/or second ORF of the inventive vector comprise the nucleotide sequences encoding SEQ ID NO:19, SEQ ID NO:3, SEQ ID NO:29, SEQ ID NO:31 , SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:13, SEQ ID NO:1 5, SEQ ID NO:39, SEQ ID NO:1 9, SEQ ID NO:35, SEQ ID NO:29 and SEQ ID NO:37 or sequence variants thereof.
  • the present invention provides for a gene expression system, which comprises at least one mammalian cell and the inventive vector, as described above, for expressing HCVM glycoproteins in said mammalian cell.
  • Such a gene expression system may be provided as a kit comprising the at least one mammalian cell, e.g. a mammalian cell culture of such mammalian cells (e.g. as a suspension of cells in a cell culture medium) and, separately, at least one vector according to the invention.
  • the inventive gene expression system is provided by at least one mammalian cell, preferably as a mammalian cell culture as mentioned above, wherein the cells are transfected by the inventive vector.
  • the mammalian cells are stably transfected by the inventive vector.
  • HCMV pentameric protein complex By such an inventive gene expression system a yield, which is several folds higher than that of conventional expression systems using adenoviruses or transfection with multiple plasmids can be achieved. Therefore, a high quantity of the HCMV pentameric protein complex can be provided, which is very useful for example in large scale production of the respective vaccine.
  • the at least one mammalian cell of the inventive gene expression system may be any appropriate mammalian producer cell, but is preferably selected from the group comprising BHK, DUXB1 1 , CHO-DG44, CHO-K1 , CHO-K1 SV, CHO-S, CHO- DXB1 1 , CHO-K1 SV GS knock-out (CHO-K1 SV KO), CAP, PER.C6, NSO, Sp2/0, HEK293 T, HEK 293-F, HEK 6E, HEK293 EBNA, CAP-T, HELA, CVI, COS, R1 610, BALBC/3T3, HAK, BFA- 1 c1 BPT, RAJI, HT-1080 and HKB-1 1 .
  • the at least one mammalian cell of the inventive gene expression system is selected from the group comprising CHO-DG44, CHO-K1 , CHO-K1 SV, CHO-S, CHO-DXB1 1 and CHO-K1 SV GS knock-out (CHO- K1 SV KO).
  • the present invention provides for a soluble protein complex obtainable by the inventive gene expression system, which preferably comprises the subunits gH, gL, UL128, UL1 30 and UL131 , preferably the respective amino acid sequences according to SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:1 1 , SEQ ID NO:21 and SEQ ID NO:25 or sequence variants thereof.
  • the complex comprises one of each of the above 5 amino acid sequences in a 1 :1 :1 :1 :1 stochiometry and, optionally, further components.
  • the complex comprises no more than one of each of the above 5 amino acid sequences, while other amino acid sequences (not comprising the immunogenic components as mentioned above) may be comprised in the inventive soluble complex.
  • Each of the above 5 immunogenic components may be provided as separate entity within the complex or may be provided by covalently coupling two or more (2 to 5) of these amino acid sequences with or without e.g. peptide linker sequences (of a length of e.g. 1 to 1 00 amino acids, preferably, 5 to 50, more preferably 5 to 30, most preferably 5 to 20 amino acids). Accordingly, the 5 amino acid sequences mentioned above may be provided as five, four, three, two or one single separate entity within the soluble protein complex.
  • the present invention provides for a soluble protein complex obtainable by the inventive gene expression system, wherein the protein complex comprises the amino acid sequences of gH, gL, UL128, UL1 30, and UL131 , in particular according to SEQ ID No: 3, SEQ ID No: 7, SEQ ID No: 1 1 , SEQ ID No: 21 and SEQ ID No: 25 or sequence variants thereof.
  • these amino acid sequences reflecting the immunogenic components may be provided as one single protein chain, e.g. by covalently linking the two to five immunogenic components with each other.
  • the above immunogenic components are separate entities, which are not covalently linked to each other and aggregate via non-covalent interaction, e.g.
  • the formation of single polypeptides containing the immunogenic components of gH, gL, UL128, UL130, and UL131 may be achieved by RNA skipping due to RNA skipping sites located between two such immunogenic components or by posttranslational protein cleavage.
  • the preferably five separate polypeptides (each containing a distinct of the above immunogenic components) forming the complex may contain each additional amino acid sequences, in particular at their N- and/or C-termini. These additional sequences arise from nucleotide sequence elements within the open reading frame(s) of the inventive vector.
  • signal peptides may be encoded by the nucleotide sequence of the open reading frame thereby elongating the immunogenic components e.g. at their termini.
  • linker sequences (or portions thereof) may elongate the immunogenic component. That holds in case of cleavage or self- processing of full length amino acid sequence in the course of translation or posttranslation as well.
  • the 5' upstream immunogenic component (according to its location in the open reading frame) may contain at its C-terminal end the N-terminal sequence of e.g. a linker element or N-terminal sequence of a self-processing motif, while the downstream immunogenic component may contain at its N-terminal end the C-terminal sequence of e.g.
  • linker sequences connecting the immunogenic components at the nucleotide sequence level may be cleaved at the protein level and may then be allocated by its N-terminal and C-terminal portions to e.g. the terminal sequences of (distinct) polypeptides comprising individually the immunogenic components as elements of the inventive soluble protein.
  • the amino acid sequence comprising e.g. a ribosomal skipping site e.g.
  • SEQ ID NOs: 5, 9, 23, 27, and 29 are separated due to the ribosomal skipping, e.g. between the GLY and the Pro residue.
  • the respective amino acid sequences are not provided by in the usual continuous structure, but are provided separately as two portions linked to two distinct polypetides, e.g. immunogenic compounds (both of which forming part of the inventive soluble complex).
  • the soluble protein complex may comprise SEQ ID NO:1 9, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:1 , SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:1 1 , SEQ ID NO:1 3, SEQ ID NO:1 5, and SEQ ID NO:1 7 or sequence variants thereof.
  • the soluble protein complex according to the invention may comprise the amino acid sequences according to SEQ ID NO:19, SEQ ID NO:35, SEQ ID NO:27, SEQ ID NO:37, SEQ ID NO:3, SEQ ID NO:27, SEQ ID NO:31 , SEQ ID NO:27, and SEQ ID NO:33 or sequence variants thereof.
  • the inventive soluble protein complex may comprise the amino acid sequences according to SEQ ID NO:35, SEQ ID NO:29, SEQ ID NO:37, SEQ ID NO:1 9, SEQ ID NO:3, SEQ ID NO:29, SEQ ID NO:31 , SEQ ID NO:29 and SEQ ID NO:33 or sequence variants thereof.
  • the inventive soluble protein complex may comprise the amino acid sequences according to SEQ ID NO:1 9, SEQ ID NO:35, SEQ ID NO:27, SEQ ID NO:37, SEQ ID NO:19, SEQ ID NO:3, SEQ ID NO:27, SEQ ID NO:31 , SEQ ID NO:27, SEQ ID NO:33, SEQ ID NO:13, SEQ ID NO:1 5, SEQ ID NO:39 and SEQ ID NO:41 or sequence variants thereof.
  • inventive soluble protein complex may comprise the amino acid sequences according to SEQ ID NO:19, SEQ ID NO:35, SEQ ID NO:29, SEQ ID NO:37, SEQ ID NO:1 9, SEQ ID NO:3, SEQ ID NO:29, SEQ ID NO:31 , SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:39 and SEQ ID NO:41 or sequence variants thereof.
  • the inventive soluble protein complex may comprise the amino acid sequences according to SEQ ID NO:1 9, SEQ ID NO:35, SEQ ID NO:27, SEQ ID NO:37, SEQ ID NO:19, SEQ ID NO:3, SEQ ID NO:27, SEQ ID NO:31 , SEQ ID NO:27, SEQ ID NO:33, SEQ ID NO:13, SEQ ID NO:1 5 and SEQ ID NO:39 or sequence variants thereof.
  • inventive soluble protein complex may comprise the amino acid sequences according to SEQ ID NO:19, SEQ ID NO:35, SEQ ID NO:29, SEQ ID NO:37, SEQ ID NO:1 9, SEQ ID NO:3, SEQ ID NO:29, SEQ ID NO:31 , SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:1 3, SEQ ID NO:1 5, SEQ ID NO:39 or sequence variants thereof.
  • the inventive soluble protein complex may comprise the amino acid sequence according to SEQ ID NO:43, or SEQ ID NO:45, or SEQ ID NO:47, or SEQ ID NO:49 or sequence variants thereof.
  • the present invention provides a soluble protein complex according to the invention (or alternatively the vector of the invention) for use as a vaccine.
  • the present invention provides for a vaccine composition, which comprises the inventive soluble protein complex and, optionally, one or more additional pharmaceutically active components and further, optionally, one or more pharmaceutically inactive components, in particular a vehicle, carrier, preservative etc.
  • the inventive vaccine composition comprises one or more adjuvants selected from the group comprising mineral salts, surface-active agents, microparticles, cytokines, hormones, detergents, squalene, Alum, polyanions or polyacrylics.
  • the adjuvant comprised in inventive vaccine composition is selected from the group consisting of Freud's incomplete or complete adjuvant, Alum, Ribi (Monophosphoryl lipid A, MPL), and MF59.
  • the inventive vaccine composition is obtainable by the use of an inventive vector or, more specifically, an inventive gene expression system.
  • the vaccine composition according to the invention elicits predominantly neutralizing antibodies and has thus a very high specific activity, which is due to the HCMV pentameric glycoprotein complex having a proper structure due to the design of the inventive vector.
  • the vaccine according to the present invention has thus a high proportion of the HCMV pentameric glycoprotein complex having a proper structure, i.e.
  • HCMV pentameric glycoprotein complex subunits gH, gL, UL128, UL1 30 and UL131 contained in the vaccine are assembled in a HCMV pentameric glycoprotein complex having the proper structure, which preferably reflects a 1 :1 :1 :1 :1 stoichiometry of these subunits and whereby the subunits preferably assume their native structure in the complex so that the HCMV pentameric glycoprotein complex preferably assumes its native structure, which is detectable e.g. by NMR spectroscopy methods. This enables a highly specific antibody response and ensures thus a high specific activity of the vaccine.
  • the vector of the invention may be formulated as a vaccine composition and may be injected into the human as well.
  • the protein complex is - under such conditions - produced in vivo and secreted from the in vivo producer cells.
  • the inventive vaccine composition may be a liquid formulation, or a solid formulation, e.g. a lyophilized formulation. If provided in a lyophilized form, which is preferred in view of transportation, stability, etc., it is preferably dissolve the lyophylized form prior to its administration.
  • the inventive vaccine composition in particular when provided in liquid form, comprises a carrier or vehicle
  • the carrier or vehicle is typically an aqueous solution, potentially being composed of a mixture of water and another organic solvent being miscible with water, e.g. ethanol, DMSO etc.
  • It may further be a buffered solution comprising a buffer preferably selected from the group of phosphate buffer, Na-acetate buffer, Tris buffer, MOPS buffer.
  • the buffer is a phosphate buffer.
  • the buffer of the inventive vaccine composition buffers the vaccine composition at a pH range of about pH 7-9, preferably between 7 and 8.
  • the vaccine composition is preferably dissolved in a carrier which is essentially isotonic.
  • the vaccine composition according to the present invention is disclosed for its use in the vaccination of a human, typically against HCMV infections, for prophylactic and/or therapeutic application, preferably for prophylactic use.
  • the present invention provides for a process of preparing a vaccine according to any one of the above embodiments.
  • the present invention provides for a nucleic acid, which comprises nucleotide sequences encoding SEQ ID NO:1 , SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:1 1 , SEQ ID NO:21 , and SEQ ID NO:25 or sequence variants thereof, or nucleotide sequences encoding SEQ ID NO:1 , SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:1 1 , SEQ ID NO:21 , SEQ ID NO:25, SEQ ID NO:1 3, SEQ ID NO:1 5 and SEQ ID NO:41 or sequence variants thereof.
  • the nucleic acid according to the invention further comprises nucleotide sequences encoding SEQ ID NO:5 and/or SEQ ID NO:9 and/or SEQ ID NO:23, and/or SEQ ID NO:27, and/or SEQ ID NO:29 or sequence variants thereof, preferably comprising SEQ ID NO:23 and/or SEQ ID NO:27 and/or SEQ ID NO:29 or sequence variants thereof.
  • the inventive nucleic acid further comprises operably linked in 5' to 3' direction the nucleic acid sequences encoding SEQ ID NO:1 , SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9 SEQ ID NO:1 1 , SEQ ID NO:1 3, SEQ ID NO:1 5, SEQ ID NO:1 7, SEQ ID NO:1 9, SEQ ID NO:21 , SEQ ID NO:23 and SEQ ID NO:25 or sequence variants thereof.
  • the inventive nucleic acid comprises operably linked in 5' to 3' direction the nucleic acid sequences encoding SEQ ID NO:1 9, SEQ ID NO:3, SEQ ID NO:27, SEQ ID NO:31 , SEQ ID NO:27, SEQ ID NO:33, SEQ ID NO:1 9, SEQ ID NO:35, SEQ ID NO:27 and SEQ ID NO:37 or sequence variants thereof.
  • the inventive nucleic acid comprises operably linked in 5' to 3' direction the nucleic acid sequences encoding SEQ ID NO:19, SEQ ID NO:3, SEQ ID NO:29, SEQ ID NO:31 , SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:1 9, SEQ ID NO:35, SEQ ID NO:29 and SEQ ID NO:37 or sequence variants thereof.
  • the nucleic acid according to the invention comprises operably linked in 5' to 3' direction the nucleic acids encoding SEQ ID NO:1 9, SEQ ID NO:3, SEQ ID NO:27, SEQ ID NO:31 , SEQ ID NO:27, SEQ ID NO:33, SEQ ID NO:1 3, SEQ ID NO:1 5, SEQ ID NO:39, SEQ ID NO:41 , SEQ ID NO:1 9, SEQ ID NO:35, SEQ ID NO:27 and SEQ ID NO:37 or sequence variants thereof.
  • the nucleic acid according to the invention comprises operably linked in 5' to 3' direction the nucleic acids encoding SEQ ID NO:1 9, SEQ ID NO:3, SEQ ID NO:29, SEQ ID NO:31 , SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:1 3, SEQ ID NO:1 5, SEQ ID NO:39, SEQ ID NO:41 , SEQ ID NO:1 9, SEQ ID NO:35, SEQ ID NO:29 and SEQ ID NO:37 or sequence variants thereof.
  • the nucleic acid according to the invention comprises operably linked in 5' to 3' direction the nucleic acids encoding SEQ ID NO:1 9, SEQ ID NO:3, SEQ ID NO:27, SEQ ID NO:31 , SEQ ID NO:27, SEQ ID NO:33, SEQ ID NO:1 3, SEQ ID NO:1 5, SEQ ID NO:39, SEQ ID NO:1 9, SEQ ID NO:35, SEQ ID NO:27 and SEQ ID NO:37 or sequence variants thereof.
  • the nucleic acid according to the invention comprises operably linked in 5' to 3' direction the nucleic acids encoding SEQ ID NO:1 9, SEQ ID NO:3, SEQ ID NO:29, SEQ ID NO:31 , SEQ ID NO:29, SEQ ID NO:33, SEQ ID NO:1 3, SEQ ID NO:1 5, SEQ ID NO:39, SEQ ID NO:1 9, SEQ ID NO:35, SEQ ID NO:29 and SEQ ID NO:37 or sequence variants thereof.
  • the inventive nucleic acid comprises the nucleotide sequence encoding SEQ ID NO:43, or SEQ ID NO:45, or SEQ ID NO:47, or SEQ ID NO:49 or sequence variants thereof.
  • the present invention pertains to the use of a nucleic acid according to the invention in a process according to any one of the above embodiments.
  • the present invention provides for a mammalian cell, e.g. a CHO cell as a mammalian producer cell, for use in a process for the preparation of a vaccine, wherein the mammalian producer cell comprises the inventive vector and/or the inventive nucleic acid according to any one of the above embodiments.
  • the process for preparing a vaccine composition according to the invention is typically composed of the following steps: (a) the vector according to the invention is prepared, (b) a mammalian producer cell, e.g.
  • a CHO cell is transfected by the vector as provided by to (a) by an in vitro step, (c) the soluble protein complex according to the invention is harvested from the mammalian producer cell, preferably after the protein complex is secreted from the producer cell into the cell environment. The harvesting is carried by appropriate techniques, e.g. be chromatographic methods.
  • the complex harvested according to (c) may optionally be further purified, and (e) the harvested and optionally purified soluble complex may thereafter be formulated as a liquid or solid formulation.
  • the present invention provides for a kit of parts, which comprises the inventive vector and at least one mammalian cell, which is used as a producer cell for producing the soluble protein complex of the invention upon transfection with the vecto of the invention.
  • the present invention provides for a method of vaccination of a human, wherein the method comprises administering to a person the inventive vaccine composition in therapeutically effective amounts. More specifically, the inventive method of vaccination of a human comprises administering 0.2 g to about 200pg of the inventive vaccine composition, wherein the vaccine composition is administered at least once, twice or three times over a period of time, e.g. within 2 to 6 weeks, and potentially and/or preferably parenterally, e.g.
  • the inventive method of vaccinating a human comprises intramuscular administration of the inventive vaccine composition. More specifically, the inventive method of vaccinating a human comprises administering the inventive vaccine composition in combination (e.g. by combined (by a single composition), or separately by subsequent or parallel administration) with one or more other HCMV vaccines.
  • Such other HCMV vaccines may be selected from the group consisting of AD1 69 HCMV strain vaccines, Towne vaccine, UL130, UL1 31 peptide conjugate vaccines, gB-based vaccines, and/ pp65 vaccine.
  • FIG. 1 Map of the inventive expression construct "pentamer2final" which was used for the nucleofection of CHO cells.
  • "2A” denotes the self-processing peptide P2A of the Foot-and- Mouth Disease virus.
  • Figure 2 Map of an inventive expression construct comprising the nucleotide sequences encoding for the HCMV glycoproteins UL128, UL130.
  • UL1 31 comprises a peptide sequence encompassing a TEV cleavage site and two STREP-Tags®.
  • FIG. 3 Characterization of a soluble HCMV pentameric complex produced in CHO-K1 SV cell line nucleofected with the inventive expression construct according to Figure 1 .
  • A SDS-PAGE and Western blot of the inventive soluble protein complex
  • B HPLC- SEC analysis of the inventive protein complex.
  • C depicts circular dichroism, far-UV spectra recorded over the wavelength range of 1 90 to 260 nm. The spectra in the far- UV region and secondary structures.
  • Panel (D) depicts CD spectra measurement of thermal denaturation performed with a T-ramp of 1 °C/minute.
  • Figure 4 A neutralization assay of HCMV using the epithelial cell line ARPE 1 9 as target and either a monoclonal human anti-HCMV antibody (5A2) as control or the soluble HCMV pentameric complex (cf. Example 3).
  • Figure 5 Binding and neutralizing antibody titers in sera of mice immunized with different doses of the HCMV pentameric complex vaccine CHO-produced pentamer.
  • Panels a and b show the binding antibody titers to gHgL dimer (a) and gHgLUL1 28L pentamer (b) measured by ELISA in the sera of mice on day +40 after immunization with different doses of the HCMV pentameric complex produced in CHO cells. Error bars show 95% CI of the geometric mean values. * P ⁇ 0.05, ** P ⁇ 0.01 .
  • Panel c shows HCMV neutralizi ng serum antibody titers measured on epithelial cells (grey circle) and fibroblasts (white circles) of mice immunized with different doses of the HCMV pentameric complex. Values were normalized to the total IgG content.
  • Panel d shows HCMV neutralizing serum antibody titers measured on epithelial cel ls (grey circle) and fibroblasts (white circles) of i ndividuals 1 month or 1 -2 years after natural HCMV infection or of mice immunized 40 days before with 0.2 pg HCMV pentameric complex. Each dot represents an individual mouse or individual (cf. Example 4).
  • Figure 6 Neutralizing and specific antibody response el icited in Balb/c mice immunized with soluble CHO-produced HCMV pentameric complex.
  • Panel a and b show normalized binding antibody titers for gHgL (a) and gHgl_pUL1 28L (b) measured by ELISA in the sera of mice on day +40 after immunization with 2.5 ⁇ g of CHO-produced pentamer formulated with different adjuvants (Alum, MF59, or Ribi). Error bars show 95% CI of the geometric mean values.
  • Panel c shows normalized neutralizing antibody titers in the sera of immunized mice measured using epithelial cells (grey dots) or fibroblasts (white dots).
  • Panel d shows data of inhibition of monoclonal antibody binding assay (IMAB).
  • IMAB monoclonal antibody binding assay
  • Figure 7 Characterization of mouse monoclonal antibodies from gB- and gHgLpUL1 28L- immunized mice.
  • Panel a shows that the percentage of HCMV neutralizing antibodies (nAbs) among HCMV glycoprotein-binding antibodies (bAbs) is significantly higher in mice immunized with the HCMV pentameric complex compared to mice immunized with the gB vaccine.
  • Panel b shows that a large fraction (67%) of the monoclonal antibodies induced by the HCMV pentameric vaccine bind epitopes present on the gHgL dimer and the gHgLpUL1 28L pentamer (cf. Example 5 and 6).
  • SEQ ID NO:2 Nucleotide sequence encoding signal peptide
  • SEQ ID NO:3 Amino acid sequence of UL128
  • SEQ ID NO:4 Nucleotide sequence encoding UL128
  • SEQ ID NO:5 Amino acid sequence T2A
  • SEQ ID NO:6 Nucleotide sequence encoding T2A
  • SEQ ID NO:7 Amino acid sequence of UL130v1
  • SEQ ID NO:8 Nucleotide sequence encoding UL130_v1
  • SEQ ID NO:9 Amino acid sequence of F2A
  • SEQ ID NO:10 Nucleotide sequence encoding F2A
  • SEQ ID NO:1 1 Amino acid sequence of UL131 v1
  • SEQ ID NO:12 Nucleotide sequence encoding UL131_v1
  • SEQ ID NO:1 3 Amino acid sequence of TEV site
  • SEQ ID NO:14 Nucleotide sequence encoding TEV site
  • SEQ ID NO:1 5 Amino acid sequence of GS linker
  • SEQ ID NO:1 6 Nucleotide sequence encoding GS linker
  • SEQ ID NO:1 7 Amino acid sequence of tandem Strep-tag_v1
  • SEQ ID NO:1 8 Nucleotide sequence encoding Strep-tag_v1
  • SEQ ID NO:1 9 Amino acid sequence of mouse IgG signal peptide
  • SEQ ID NO:20 Nucleotide sequence encoding mouse IgG signal peptide
  • SEQ ID NO:21 Amino acid sequence of gH_v1
  • SEQ ID NO:22 Nucleotide Sequence encoding gH_v1
  • SEQ ID NO:23 Amino acid sequence of P2A
  • SEQ ID NO:24 Nucleotide sequence encoding P2A
  • SEQ ID NO:25 Amino acid sequence of gL_v1
  • SEQ ID NO:26 Nucleotide sequence encoding gL_v1
  • SEQ ID NO:27 Amino acid sequence of P2A_v2
  • SEQ ID NO:28 Nucleotide sequence encoding P2A_v2
  • SEQ ID NO:29 Amino acid sequence of P2A_v3
  • SEQ ID NO:30 Nucleotide sequence encoding P2A_v3
  • SEQ ID NO:31 Amino acid sequence encoding UL1 30_v2
  • SEQ ID NO:32 Nucleotide sequence encoding UL1 30_v2
  • SEQ ID NO:33 Amino acid sequence of UL131 _v2
  • SEQ ID NO:34 Nucleotide sequence encoding ULl 31 _v2
  • SEQ ID NO:35 Amino acid sequence of gHv2 SEQ ID NO:36 Nucleotide sequence encoding gHv2
  • sequence variant refers to any alteration in a reference sequence, whereby a reference sequence is any of the sequences listed in the SEQUENCE LISTING, i.e. SEQ ID NO:1 to SEQ ID NO:55.
  • sequence variant includes nucleotide sequence variants and amino acid sequence variants.
  • nucleotide sequence variant has an altered sequence in which one or more of the nucleotides in the reference sequence is deleted, or substituted, or one or more nucleotides are inserted into the sequence of the reference nucleotide sequence. Nucleotides are referred to herein by the standard one-letter designation (A, C, G, or T). Due to the degeneracy of the genetic code, a “nucleotide sequence variant” can either result in a change in the respective reference amino acid sequence, i.e. in an "amino acid sequence variant” or not.
  • Preferred sequence variants are such nucleotide sequence variants, which do not result in amino acid sequence variants (silent mutations), but other non-silent mutations are within the scope as well, in particular mutant nucleotide sequences, which result in an amino acid sequence, which is at least 80%, preferably at least 90 %, more preferably at least 95% sequence identical to the reference sequence.
  • An "amino acid sequence variant” has an altered sequence in which one or more of the amino acids in the reference sequence is deleted or substituted, or one or more amino acids are inserted into the sequence of the reference amino acid sequence.
  • the amino acid sequence variant has an amino acid sequence which is at least 80% identical to the reference sequence, preferably, at least 90% identical, more preferably at least 95% identical, most preferably at least 99% identical to the reference sequence.
  • Variant sequences which are at least 90% identical have no more than 10 alterations, i.e. any combination of deletions, insertions or substitutions, per 1 00 amino acids of the reference sequence. Percent identity is determined by comparing the amino acid sequence of the variant with the reference sequence using computer programs well-known in the art, in particular according to the MEGALIGN project in the DNA STAR program.
  • conservative amino acid substitutions involve substitution of one aliphatic or hydrophobic amino acids, e.g. alanine, valine, leucine and isoleucine, with another; substitution of one hydoxyl-containing amino acid, e.g. serine and threonine, with another; substitution of one acidic residue, e.g. glutamic acid or aspartic acid, with another; replacement of one amide-containing residue, e.g.
  • Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include the fusion to the N- or C-terminus of an amino acid sequence to a reporter molecule or an enzyme.
  • the alterations in the sequence variants do not abolish the functionality of the respective reference sequence, in the present case e.g. the functionality of mutant immunogenic components to trigger an immune response of sufficient strength.
  • Guidance in determining which nucleotides and amino acid residues, respectively, may be substituted, inserted or deleted without abolishing such functionality are found by using computer programs well known in the art, for example, DNASTAR software.
  • a pentameric soluble protein complex vaccine obtainable by the inventive vector, which encodes the HCMV glycoproteins gH, gL, pUL128, pUL1 30 and pUL131 results in the formation of high numbers of predominantly neutralizing antibodies against HCMV infection of fibroblasts, epithelial, endothelial, and myeloid cells.
  • the protein and gene encoding for HCMV glycoprotein UL128, UL1 30, or UL131 A may be referred to as pUL128, pUL1 30, pUL131 , or UL131 , respectively.
  • the HCMV pentameric complex formed by the surface glycoproteins gH, gL, pUL128, pUL130 and pUL131 A may e.g. also referred to as gHgLpUL128L, or HCMV pentameric complex, or HCMV pentamer, or pentamer.
  • the present invention provides for a vector for expressing HCMV glycoproteins in a mammalian cell and wherein the vector comprises a transcription system.
  • This transcription system comprises in general
  • the vector comprises each of the nucleotide sequences selected from the group consisting of nucleotide sequences encoding the HCMV glycoproteins gH, gL, pUL128, pUL1 30 and pUL131 or sequence variants thereof, i.e. an amino acid sequence according to SEQ ID NO:21 , SEQ ID NO:25, SEQ ID NO:3, SEQ ID NO:7 and SEQ ID NO:1 1 or the sequence variants thereof.
  • the preferred nucleotide sequences encoding gH and gL are according to SEQ ID NO:22, SEQ ID NO:26 or sequence variants thereof and the preferred nucleotide sequences encoding pUL128, pUL130 and pUL13 l are according to SEQ ID NO:4, SEQ ID NO:8 and SEQ ID NO:12 or sequence variants thereof , respectively.
  • the inventive vector preferably comprises at least two transcription units, each of which comprises an ORF, operably linked to a promoter.
  • Each of the ORFs may further comprise e.g. a 5' start codon and encodes two or more HCMV viral glycoproteins, such as e.g. gH (e.g. by SEQ ID NO:22), gL (e.g. by SEQ ID NO:26), pUL128 (e.g. by SEQ ID NO:4), pUL1 30 ( e.g. by SEQ ID NO:8), or pULI 31 (e.g. by SEQ ID NO:12), or sequence variants thereof.
  • gH e.g. by SEQ ID NO:22
  • gL e.g. by SEQ ID NO:26
  • pUL128 e.g. by SEQ ID NO:4
  • pUL1 30 e.g. by SEQ ID NO:8
  • pULI 31 e.g. by SEQ
  • the vector of the inventive gene expression system comprises operably linked (i) a first promoter operable in a mammalian cell, (ii) a first open reading frame (ORF), which comprises a 5' start codon, and a nucleotide sequence, which comprises SEQ ID NO:22 and SEQ ID NO:26 or sequence variants thereof, (iii) a second promoter operable in said mammalian cell and (iv) a second open reading frame (ORF), which comprises a 5' start codon and a nucleotide sequence according to SEQ ID NO:4, SEQ ID NO:8 and SEQ ID NO:12 or sequence variants thereof.
  • the ORFs may e.g. further comprise nucleotide sequences which encode one or more of the self- processing peptides of the Foot-and- Mouth Disease virus, such as e.g. P2A (e.g. SEQ ID NO:24), T2A (e.g. SEQ ID NO:6), or F2A (e.g. SEQ ID NO:10), which will result in ribosomal skipping, which impairs normal peptide bond formation upon translation and results in the generation of two or more proteins from one mature mRNA (cf. for example Palmenberg, A.C. et al. Virology 190, 754-762 (1992)).
  • P2A e.g. SEQ ID NO:24
  • T2A e.g. SEQ ID NO:6
  • F2A e.g. SEQ ID NO:10
  • the 2A peptide consensus motif which is typically associated with cleavage activity is Asp-Val/lle-Glu-X-Asn-Pro-Gly-(P2B-Pro) and will result in cleavage between the P2A glycine and the 2 B proline.
  • Other peptide sequences that result in ribosomal skipping may be also be used in the present invention for the generation of two or more, e.g. two or three, HCMV glycoproteins from one mature mRNA, such as e.g. T2A (e.g. SEQ ID NO:5), or F2A (e.g. SEQ ID NO:9).
  • vector refers to a nucleic acid, into which fragments of nucleic acid may be inserted or cloned and which is typically a plasmid, a viral vector, a cosmid or an artificial chromosome, whereby a plasmid is preferred.
  • the vector is an expression vector, which is optimized for the expression of a peptide or a protein, whereby an expression vector suitable for a mammalian expression system is particularly preferred. Accordingly, it is particularly preferred that a sequence used in the vector, most preferably all sequences used in the vector, are codon optimized for expression in mammalian cells.
  • the term "vector” as used herein refers to a single entity, e.g. one plasmid is one vector, whereas five plasmids are five vectors.
  • the vector is a DNA construct.
  • the vector may contain one or more unique restriction sites for this purpose, and may be capable of autonomous replication in a defined host or organism such that the cloned sequence is reproduced.
  • the vector molecule may confer some well-defined phenotype on the host organism which is either selectable or readily detected.
  • Some components of a vector may be a DNA molecule further incorporating a DNA sequence encoding regulatory elements for transcription, translation, RNA stability and replication, or e.g. antibiotic selection.
  • the vector may e.g. also comprise nucleotide sequences which encode peptide or protein moieties which will facilitate the purification of encoded inventive protein products, such as e.g. 6xHis-tag (e.g. SEQ ID NO:42), or e.g.
  • a Strep-tag ® (e.g. SEQ ID NO:1 8 or SEQ ID NO:40), which may for example be coupled to a cleavage site, e.g. a TEV cleavage site (e.g. SEQ ID NO:14).
  • a cleavage site e.g. a TEV cleavage site (e.g. SEQ ID NO:14).
  • the vector may further comprise e.g. spacer sequences between the individual tags, such as e.g. a GS linker according to SEQ ID NO:1 6.
  • the sequences may e.g. be comprised on the vector singly, or preferably in combination, such as e.g. in 5'-3' direction SEQ ID NO:1 4, SEQ ID NO:42, SEQ ID NO:1 6 and SEQ ID NO:18 or sequence variants thereof, or e.g. SEQ ID NO:14, SEQ ID NO:42, SEQ ID NO:42, SEQ ID NO:1 6 and SEQ ID NO:40 or sequence variants thereof, or e.g.
  • SEQ ID NO:14 and SEQ ID NO:42 or sequence variants thereof or e.g. SEQ ID NO:1 6, SEQ ID ⁇ : ⁇ 4 and SEQ ID NO:42 or sequence variants thereof, or e.g. SEQ ID NO:14, SEQ ID NO:1 6 and SEQ ID NO:42 or sequence variants thereof, or e.g. SEQ ID NO:14 and SEQ ID NO:18 or sequence variants thereof, or e.g. SEQ ID NO:14 and SEQ ID NO:40 or sequence variants thereof.
  • the sequences as disclosed above may e.g. be comprised on the 5' end, or e.g.
  • each of the ORFs of the inventive transcription system as part of the inventive vector, preferably, the sequences as disclosed above are 3' or at the 3' end of at least one of the ORFs of the inventive transcriptions system, e.g. the sequences may be present at the 3' end of a first ORF of the inventive transcription system, or e.g. at the 3' end of a second ORF, or e.g. may be present at the 3' ends of a first and second ORF of the inventive vector.
  • the vector may also comprise sequences, which facilitate the secretion of the proteins encoded by the nucleotide sequences as disclosed in the present invention, e.g. the vector of the inventive gene expression system may comprise signal peptides.
  • the term "signal peptide" (sometimes referred to as signal sequence, leader sequence or leader peptide) as used in the present invention refers to a peptide of typically 5-30 amino acids in length present at the N-terminus of the majority of newly synthesized proteins that are destined towards the secretory pathway.
  • Signal peptides may be artificial, or may be derived from immunoglobulins, such as e.g. the murine IgG signal peptide (e.g.
  • a first and/or a second ORF of the inventive vector may comprise as a 5' sequence a signal peptide sequence as defined above, or e.g. any one of the HCMV surface glycoproteins as disclosed herein and as encoded in a first and/or second ORF may e.g. comprise a signal sequence, e.g. SEQ ID NO:20, or SEQ ID NO:2, or sequence variants thereof, on their respective 5' ends, or e.g.
  • the HCMV surface glycoproteins as disclosed in the present invention may comprise at their N-terminus a signal peptide according to SEQ ID NO:1 , or SEQ ID NO:1 9, or sequence variants thereof.
  • sequence encoding the gH signal peptide may preferably be replaced by a sequence encoding the IgG leader sequence, e.g. SEQ ID NO:2 or sequence variants thereof.
  • promoter refers to a nucleotide sequence, preferably a DNA sequence, that determines the site of transcription initiation of RNA polymerase, e.g. a promoter may be a regulatory sequence within about 200 base pairs of the transcription start site of RNA polymerase II (RNAP II), but may also comprise DNA sequence elements within -1 OOObp to about -1 OObp of the transcription start site of RNAP II.
  • the first promoter of the inventive gene expression system may be e.g. a murine CMV promoter (MCMV), a human CMV (HCMV), a SV40, a HSV-TK, an EF1 -1 or PGK promoter.
  • a first promoter of the inventive vector is preferably one of a MCMV, a HCMV, a SV40, a HSV-TK, an EF1 -1 a or PGK promoter.
  • a first promoter may be e.g. a MCMV promoter, or e.g. a HCMV promoter, or e.g. a SV40 promoter, or e.g. a HSV-TK promoter, or e.g.
  • the at least one ORF of the inventive vector may preferably further comprise a first promoter and operably linked in 5' - 3' direction nucleotide sequences encoding gH and gL, e.g. nucleotide sequences according to SEQ ID NO:22 and SEQ ID NO:26 or sequence variants thereof.
  • the promoter of the inventive vector may also be e.g. an inducible promoter, such as the tetracycline-inducible promoter (Gossen and Bujard, (1992) PNAS Jun 1 5;89(12):5547-51 ), or an IPTG-inducible system (e.g. such as that disclosed by Grespy et al. PLoS One. 201 1 Mar 21 ;6(3):e18051 ), which allow for a temporal control of gene expression of the genes operably linked to the first promoter of the inventive gene expression system.
  • the at least one ORF of the inventive vector may preferably further comprise a 5' start codon, e.g.
  • the start codon of the at least one ORF of the inventive gene expression system may e.g. also be comprised in a Kozak sequence, e.g. the 5' start codon may be comprised in the sequence 5'-GCCACCATG or the start codon may be downstream of the Kozak sequence, which results in an improved translation efficacy of the matured RNAP II transcript.
  • the vector may preferably further comprise a second promoter as defined above, e.g. a promoter identical or different to a first promoter of the inventive gene expression system, such as e.g. murine CMV promoter (MCMV), a human CMV (HCMV), a SV40, a HSV-TK, an EF1 -1 or PGK promoter.
  • a second promoter as defined above, e.g. a promoter identical or different to a first promoter of the inventive gene expression system, such as e.g. murine CMV promoter (MCMV), a human CMV (HCMV), a SV40, a HSV-TK, an EF1 -1 or PGK promoter.
  • the vector of the inventive gene expression system may comprise e.g. as first and second promoter (MCMV) and as second promoter a human CMV, or e.g. as first promoter a SV40 and as second promoter a HSV-TK, or e.g.
  • first promoter an EF1 -1 promoter and as second promoter a PGK promoter or e.g. as first and second promoter an MCMV promoter, or e.g. as first and second promoter an HCMV promoter, or e.g. a SV40 promoter as first promoter and a MCMV promoter as second promoter, or e.g. a HCMV promoter as first promoter and a SV40 promoter as second promoter, or e.g. an inducible promoter, such as e.g. tetO as first and second promoter, or e.g. an EF-1 promoter as first and second promoter, or e.g. an EF-1 promoter as first promoter and a PGK promoter as second promoter.
  • a second promoter of the inventive vector is preferably one of a MCMV, a HCMV, a SV40, a HSV-TK, an EF1 -1 a or PGK promoter.
  • a second promoter may be e.g. a MCMV promoter, or e.g. a HCMV promoter, or e.g. a SV40 promoter, or e.g. a HSV-TK promoter, or e.g. an EF1 -1 a promoter or e.g. a PGK promoter as defined above.
  • the inventive vector further comprises a second ORF, which comprises a 5' start codon as defined above and the nucleotide sequence encoding SEQ ID NO:4, SEQ ID NO:8 and SEQ ID NO:12 or sequence variants thereof.
  • the second ORF of the inventive gene expression system comprises a 5' start codon, e.g. a 5' start codon.
  • the start codon may be comprised by the Kozak sequence as defined above or may be downstream of the Kozak sequence and a nucleic sequence encoding SEQ ID NO:4, SEQ ID NO:8 and SEQ ID NO:12 or sequence variants thereof, or e.g.
  • SEQ ID NO:8 SEQ ID NO:4 and SEQ ID NO:12 or sequence variants thereof, or e.g. SEQ ID NO:12, SEQ ID NO:8 and SEQ ID NO:4 or sequence variants thereof, or e.g. SEQ ID NO:12, SEQ ID NO:4 and SEQ ID NO:8 or sequence variants thereof.
  • a second ORF of the inventive vector may comprise at least a 5' start codon and a nucleotide sequence encoding SEQ ID NO:4, SEQ ID NO:8 or sequence variants thereof and SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:1 6, SEQ ID NO:1 8 and SEQ ID NO:42 or sequence variants thereof.
  • a second ORF of the inventive vector may comprise a start codon as defined above, and a nucleotide sequence encoding SEQ ID NO:4, SEQ ID NO:8 and SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:1 6, SEQ ID NO:18 and SEQ ID NO:42 or sequence variants thereof, or e.g.
  • SEQ ID NO:8 SEQ ID NO:4 and SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:1 6, SEQ ID NO:1 8 and SEQ ID NO:42 or sequence variants thereof, or e.g. SEQ ID NO:12, SEQ ID NO:8 and SEQ ID NO:4, SEQ ID NO:14, SEQ ID NO:1 6, SEQ ID NO:1 8 and SEQ ID NO:42 or sequence variants thereof.
  • the individual sequence elements, e.g. SEQ ID NO:4, SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:1 6, SEQ ID NO:1 8 and SEQ ID NO:42 or sequence variants thereof may e.g. be a continuous sequence, or e.g. be separated by nucleotide sequences, for as long as the reading frame of the second ORF is not changed.
  • the inventive vector comprises a first and second ORF, wherein the first and/or second ORF each preferably comprise at least one or more nucleotide sequences selected from the group consisting of nucleotide sequences encoding the HCMV glycoproteins gH, gL, pUL128, pUL1 30 and pUL131 or sequence variants thereof, i.e. an amino acid sequence according to SEQ ID NO:21 , SEQ ID NO:25, SEQ ID NO:3, SEQ ID NO:7 and SEQ ID NO:1 1 or sequence variants thereof, e.g.
  • the first ORF of the inventive gene expression system as defined above may comprise SEQ ID NO:6 and/or SEQ ID NO:10 and/or SEQ ID NO:24 and/or SEQ ID NO:28 and/or SEQ ID NO:30 or sequence variants thereof, e.g. the first ORF as defined above may comprise SEQ ID NO:6, or SEQ ID NO:10, or SEQ ID NO:24, or SEQ ID NO:28 or SEQ ID NO:30 or sequence variants thereof, or e.g.
  • the first ORF may comprise SEQ ID NO:22, SEQ ID NO:6, SEQ ID NO:26 or sequence variants thereof, or e.g. SEQ ID NO:22, SEQ ID NO:10, SEQ ID NO:26, or e.g. SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26 or sequence variants thereof, or e.g. SEQ ID NO:22, SEQ ID NO:28, SEQ ID NO:26, or e.g.
  • the first ORF of the inventive vector may e.g. further also comprise a signal peptide, in particular for secretion to the extracellular environment, e.g. encoding SEQ ID NO:19 or sequence variants thereof by e.g. SEQ ID NO:20 or sequence variants thereof, e.g. the first ORF may comprise operably linked a 5' start codon and SEQ ID NO:20 or a sequence variant thereof.
  • the nucleotide sequence may further comprise a KOZAK sequence as defined above to improve translation initiation of the resulting mRNA.
  • the second ORF of the inventive vector may preferably comprise at least one or more nucleotide sequences selected from the group consisting of nucleotide sequences encoding the HCMV glycoproteins gH, gl_, pUL128, pUL130 and pUL131 or sequence variants thereof, i.e. an amino acid sequence according to SEQ ID NO:21 , SEQ ID NO:25, SEQ ID NO:3, SEQ ID NO:7 and SEQ ID NO:1 1 or sequence variants thereof, e.g.
  • the second ORF of the inventive gene expression system may e.g. comprise SEQ ID NO:6, or SEQ ID NO:1 0, or SEQ ID NO:24, or SEQ ID NO:28, or SEQ ID NO:30 or sequence variants thereof, or e.g. SEQ ID NO:6, SEQ ID NO:1 0 or sequence variants thereof, or e.g. SEQ ID NO:6, SEQ ID NO:24 or sequence variants thereof, or e.g.
  • SEQ ID NO:6, SEQ ID NO:28 or sequence variants thereof or e.g. SEQ ID NO:6, SEQ ID NO:30 or sequence variants thereof, or e.g. SEQ ID NO:10, SEQ ID NO:24 or sequence variants thereof, or e.g. SEQ ID NO:10, SEQ ID NO:28, or e.g. SEQ ID NO:30 or sequence variants thereof, or e.g. SEQ ID NO:24, SEQ ID NO:28 or sequence variants thereof, or e.g. SEQ ID NO:30 or sequence variants thereof.
  • the first and second ORF of the inventive vector may comprise SEQ ID NO:6 and/or SEQ ID NO:10 and/or SEQ ID NO:24 and/or SEQ ID NO:28 and/or SEQ ID NO:30 or sequence variants thereof, e.g. SEQ ID NO:6, or SEQ ID NO:6, or SEQ ID NO:1 0, or SEQ ID NO:24, or SEQ ID NO:28, or SEQ ID NO:30 or sequence variants thereof, or e.g. SEQ ID NO:6, SEQ ID NO:10 or sequence variants thereof, or e.g. SEQ ID NO:6, SEQ ID NO:24 or sequence variants thereof, or e.g.
  • a first and second ORF of the inventive vector preferably each comprise at least one nucleotide sequence according to SEQ ID NO:24 and/or SEQ ID NO:28 and/or SEQ ID NO:30 or sequence variants thereof.
  • the first and second ORF of the inventive gene expression system may e.g. each comprise at least one nucleotide sequence according to SEQ ID NO:24, or SEQ ID NO:28, or SEQ ID NO:30 or sequence variants thereof, e.g. the first ORF may comprise SEQ ID NO:24, or SEQ ID NO:28, or SEQ ID NO:30 or sequence variants thereof, while the second ORF may comprise e.g.
  • SEQ ID NO:24 and SEQ ID NO:28 or sequence variants thereof or e.g. SEQ ID NO:24 and SEQ ID NO:30 or sequence variants thereof, or e.g. SEQ ID NO:28 and SEQ ID NO:30 or sequence variants thereof.
  • the vector according to the present invention comprises a first ORF, which comprises operably linked the nucleotide sequence sequences according to SEQ ID NO:20, SEQ ID NO:22 and SEQ ID NO:24 and SEQ ID NO:26, or the nucleotide sequences according to SEQ ID NO:20, SEQ ID NO:36, SEQ ID NO:28 and SEQ ID NO:38, or the nucleotide sequences according to SEQ ID NO:20, SEQ ID NO:36, SEQ ID NO:30 and SEQ ID NO:38, and a second ORF comprises operably linked SEQ ID NO:4, SEQ ID NO:24, SEQ ID NO:8, SEQ ID NO:24, and SEQ ID NO:12, or operably linked SEQ ID NO:4, SEQ ID NO:24, SEQ ID NO:8, SEQ ID NO:24, and SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:1 6, SEQ ID NO: 18 and SEQ ID NO:42.
  • a second ORF comprises
  • the first ORF of the inventive gene expression system may comprise operably linked the nucleic acid sequences according to e.g. SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24 and SEQ ID NO:26, or e.g. SEQ ID NO:20, SEQ ID NO:36, SEQ ID NO:28 and SEQ ID NO:38, or e.g. SEQ ID NO:20, SEQ ID NO:36, SEQ ID NO:30 and SEQ ID NO:38, or e.g. SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:6 and SEQ ID NO:26, or e.g.
  • the second ORF of the inventive gene expression system may comprise operably linked SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:24, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:1 2, SEQ ID NO:14, SEQ ID NO:1 6, SEQ ID NO:1 8 and SEQ ID NO:42, or e.g. SEQ ID NO:20, SEQ ID NO:4, SEQ ID NO:10, SEQ ID NO:32, SEQ ID NO:10, SEQ ID NO:34, and SEQ ID NO:40, or e.g.
  • SEQ ID NO:20, SEQ ID NO:4, SEQ ID NO:24, SEQ ID NO:32, SEQ ID NO:24, SEQ ID NO:34, and SEQ ID NO:40 or e.g. SEQ ID NO:20, SEQ ID NO:4, SEQ ID NO:28, SEQ ID NO:32, SEQ ID NO:28, SEQ ID NO:34, and SEQ ID NO:40, or e.g. SEQ ID NO:20, SEQ ID NO:4, SEQ ID NO:28, SEQ ID NO:32, SEQ ID NO:28, and SEQ ID NO:34, or e.g.
  • SEQ ID NO:20, SEQ ID NO:4, SEQ ID NO:24, SEQ ID NO:32, SEQ ID NO:24, and SEQ ID NO:34 or e.g. SEQ ID NO:20, SEQ ID NO:4, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:30, and SEQ ID NO:34, or e.g. SEQ ID NO:20, SEQ ID NO:4, SEQ ID NO:28, SEQ ID NO:8, SEQ ID NO:28, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:1 6, SEQ ID NO:1 8 and SEQ ID NO:42, or e.g.
  • SEQ ID NO:4 SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:30, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:1 6, SEQ ID NO:40 and SEQ ID NO:42, or e.g. SEQ ID NO:20, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:32, SEQ ID NO:6, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:1 6, SEQ ID NO:18 and SEQ ID NO:42, or e.g.
  • SEQ ID NO:2 SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:32, SEQ ID NO:6, SEQ ID NO:34, SEQ ID NO:14, SEQ ID NO:1 6, SEQ ID NO:18 and SEQ ID NO:42, or e.g. SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:10, SEQ ID NO:32, SEQ ID NO:10, SEQ ID NO:12, SEQ ID N0:14, SEQ ID NO:1 6, SEQ ID NO:1 8 and SEQ ID NO:42, or e.g.
  • SEQ ID NO:2 SEQ ID NO:4, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:30, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:1 6, SEQ ID NO:1 8 and SEQ ID NO:42, or e.g. SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:24, SEQ ID NO:8, SEQ ID NO:24, SEQ ID NO:12, or e.g. SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:6, and SEQ ID NO:12, or e.g.
  • SEQ ID NO:20, SEQ ID NO:4, SEQ ID NO:10, SEQ ID NO:32, SEQ ID NO:10, and SEQ ID NO:34 or e.g. SEQ ID NO:20, SEQ ID NO:4, SEQ ID NO:10, SEQ ID NO:32, SEQ ID NO:1 0, and SEQ ID NO:12, or e.g. SEQ ID NO:20, SEQ ID NO:4, SEQ ID NO:24, SEQ ID NO:32, SEQ ID NO:24, and SEQ ID NO:12 or e.g. SEQ ID NO:20, SEQ ID NO:4, SEQ ID NO:28, SEQ ID NO:32, SEQ ID NO:28, and SEQ ID NO:12, or e.g.
  • SEQ ID NO:20, SEQ ID NO:4, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:30, and SEQ ID NO:12 preferably e.g. SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:1 6, SEQ ID NO:1 8, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24 and SEQ ID NO:26, or e.g.
  • SEQ ID NO:2 SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:1 0, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:1 6, SEQ ID NO:1 8, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24 and SEQ ID NO:26, or e.g. SEQ ID NO:20, SEQ ID NO:4, SEQ ID NO:28, SEQ ID NO:32, SEQ ID NO:28, SEQ ID NO:34, SEQ ID NO:20, SEQ ID NO:36, SEQ ID NO:28 and SEQ ID NO:38, or e.g.
  • the present invention provides for a gene expression system, which comprises at least one mammalian cell and a vector according to the invention, e.g. as described above, for expressing HCMV glycoproteins in said mammalian cell, wherein the vector comprises a transcription system.
  • the inventive gene expression system thus comprises at least one mammalian cell, e.g.
  • the inventive gene expression system may comprise least one mammalian cell, or at least 10, or at least 100, or at least 1000, or at least about 10,000 cells, or of at least about 10 5 , 10 6 , 107, 10 8 , 10 9 , 10 10 , 10' 1 , 1 0 12 mammalian cells, or e.g. of about 1 0 3 cells/ml, or of about 10 4 cells/ml, to about 10 9 cells/ml, e.g.
  • the inventive gene expression system may comprise e.g. at least 10 2 cells/cm 2 to about 1 0 6 cells/cm 2 , if the at least one mammalian cell is grown on a solid support, e.g. 1 0 2 , 10 3 , 10 4 , 10 s or 10 6 cells/cm 2 , or e.g.
  • the at least one mammalian cell comprised in the gene expression system according to the invention is selected from the group comprising BHK, DUXB1 1 , CHO-DG44, CHO-K1 , CHO-K1 SV, CHO-S, CHO-DXB1 1 , CHO-K1 SV GS knock-out (CHO-K1 SV KO), CAP, PER.C6, NS0, Sp2/0, HEK293 T, HEK 293-F, HEK 6E, HEK293 EBNA, CAP-T, HELA, CVI, COS, R1 610, BALBC/3T3, HAK, BFA-1 c1 BPT, RAJI, HT-1080, HKB-1 1 .
  • the inventive gene expression system may comprise at least one mammalian cell as defined above, preferably the at least one mammalian cell is selected from the group comprising CHO-DG44, CHO-K1 , CHO-K1 SV, CHO-S, CHO-DXB1 1 , CHO-K1 SV CS knock-out (CHO- Kl SV KO) cells.
  • the at least one mammalian cell of the inventive gene expression system as defined above may be a CHO-DG44 cell, or e.g. a CHO-K1 cell, or e.g. a CHO-K1 SV cell, or e.g. a CHO-S cell, or e.g. a CHO-DXB1 1 cell, or e.g. a CHO-K1 SV GS knock-out (CHO- Kl SV KO) cell.
  • the mammalian cell is transfected by the vector according to the invention.
  • transfected or “transfection” as used herein refers to deliberately introducing nucleic acids, e.g. the inventive vector, into cells.
  • the transfection may be transient, i.e. the introduced nucleic acid is usually not integrated in the nuclear genome and the transfected genetic material is only transiently expressed, or stable, whereby the introduced nucleic acid is integrated in the genome (also referred to as "nucleofection").
  • the mammalian cell is stably transfected by the inventive vector.
  • the present invention provides for a soluble protein complex, which is obtainable by the inventive gene expression system as described above, wherein it is preferred that the protein complex comprises the amino acid sequences according to SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:1 1 , SEQ ID NO:21 and SEQ ID NO:25 or sequence variants thereof, or SEQ ID NO:45 or sequence variants thereof, or SEQ ID NO:47 or sequence variants thereof, or SEQ ID NO:49 or sequence variants thereof.
  • inventive soluble protein complex obtainable by the inventive gene expression system as disclosed above may comprise the amino acid sequences according to SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:1 1 , SEQ ID NO:21 and SEQ ID NO:25 or sequence variants thereof, or SEQ ID NO:45 or sequence variants thereof, or SEQ ID NO:47 or sequence variants thereof, or SEQ ID NO:49 or sequence variants thereof, e.g. HCMV proteins UL128, UL130, UL131 , gH and gL, which may be encoded by e.g.
  • nucleotide sequences according to SEQ ID NO:4, SEQ ID NO:8, SEQ ID NO:1 2, SEQ ID NO:22 and SEQ ID NO:26 or sequence variants thereof or e.g. by SEQ ID NO:46 or sequence variants thereof, or by e.g. SEQ ID NO:48 or sequence variants thereof, or by e.g. SEQ ID NO:50 or sequence variants thereof.
  • the term "obtainable” as used herein in the context of the inventive soluble protein complex as disclosed above shall mean that the polypeptide encoded by the nucleotide sequence may be produced by the at least one mammalian cell as disclosed above, in which the nucleotide sequences according to the invention, are present, e.g. the nucleotide sequences may be comprised on an inventive expression vector.
  • protein complex refers to a composite unit that is a combination of two or more proteins formed by interaction between the proteins.
  • a “protein complex” is formed by the binding and/or interaction of two or more proteins through specific, non-covalent binding interactions.
  • the protein complex may also be formed by e.g. covalent linkage of the individual proteins of the complex, such as e.g. by a peptide bond or by means of a peptide linker sequence, which via peptide bonds joins two proteins.
  • two or more proteins e.g. two, three, four or five (e.g all of the) proteins of the inventive soluble protein complex comprising gH, gL, pUL128, pUL130 and pUL131 may be linked via peptide linker.
  • the peptide linker for use with the inventive soluble protein complex is of sufficient length and provides sufficient flexibility such that it does not interfere with the folding and/or assembly of the protein complex, such that the conformation of the inventive soluble protein complex is retained.
  • the linker sequence may comprise the amino acid sequence according to SEQ ID NO:1 5 or sequence variants thereof, or e.g. may comprise the amino acid sequence GSTSGSGXPGSGEGSTKG (SEQ ID NO:51 ) as disclosed in WOl 994/012520, whereby X represents a charged amino acid, or.g. the amino acid sequence Ser-Ser-Ser-Ser-Gly as disclosed in US5525491 , or e.g. Gly-Gly-Gly- Gly-Ser-Gly-Gly-Gly-Gly-Gly-Ser-Gly-Gly (SEQ ID NO:52) as disclosed in WO2002046227, or e.g.
  • inventive soluble protein complex may thus comprise the proteins gH, gL, UL128, UL130 and UL131 linked to each other by means of any of e.g. the above sequences, e.g. the HCMV surface glycoproteins, or sequence variants thereof as disclosed in the present invention, may be in the order of e.g.
  • peptide linkers as disclosed above are typically encoded as part of a first and second ORF of the inventive transcription system and the corresponding nucleotide sequences encoding the peptide linker as disclosed above are located in frame between two, e.g.
  • the use of the peptide linker sequences, or their corresponding nucleotide sequence may be comprised in a single ORF of a vector of the inventive gene expression system, which may e.g. result in the translation of a single, self-processing polypeptide, if nucleotide sequences (e.g. SEQ ID NO:6, 10, 24, 28 or 30 or sequence variants thereof) encoding the self-processing peptides as disclosed above are present in the ORF.
  • nucleotide sequences e.g. SEQ ID NO:6, 10, 24, 28 or 30 or sequence variants thereof
  • the two or more proteins of the inventive soluble protein complex can be covalently linked by e.g. disulfide bonds, which may result in a stabilization of the protein complex.
  • Non- covalent binding interactions as referred to above may include e.g. van der Waals interactions, or e.g. ionic interactions between differently charged amino acid residues.
  • the present invention provides for a soluble protein complex, which is obtainable by the inventive gene expression system as defined above, wherein the protein complex may comprise the amino acid sequences according to SEQ ID NO:19, SEQ ID NO:21 , SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:1 , SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:1 1 , SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:1 7 or sequence variants thereof.
  • the soluble protein complex according to the invention may comprise the amino acid sequences according to SEQ ID NO:19, SEQ ID NO:21 , SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:1 , SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:1 1 , SEQ ID NO:13, SEQ ID NO:1 5, SEQ ID NO:1 7 or sequence variants thereof, or e.g.
  • inventive soluble protein complex may comprise the amino acid sequences encoded by nucleotide sequences SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:1 6, SEQ ID NO:1 8 or sequence variants thereof.
  • the present invention provides for a soluble protein complex, which is obtainable by the inventive gene expression system as defined above, wherein the protein complex may comprise the amino acid sequences according to SEQ ID NO:1 9, SEQ ID NO:35, SEQ ID NO:27, SEQ ID NO:37, SEQ ID NO:1 9, SEQ ID NO:3, SEQ ID NO:27, SEQ ID NO:31 , SEQ ID NO:27, SEQ ID NO:3 or sequence variants thereof.
  • inventive soluble protein complex obtainable by the inventive gene expression system may comprise the amino acid sequences according to SEQ ID NO:19, SEQ ID NO:35, SEQ ID NO:29, SEQ ID NO:37, SEQ ID NO:19, SEQ ID NO:3, SEQ ID NO:29, SEQ ID NO:31 , SEQ ID NO:29, SEQ ID NO:33 or sequence variants thereof.
  • inventive soluble protein complex obtainable by a gene expression system according to the invention may comprise the amino acid sequences according to SEQ ID NO:1 9, SEQ ID NO:35, SEQ ID NO:27, SEQ ID NO:37, SEQ ID NO:19, SEQ ID NO:3, SEQ ID NO:27, SEQ ID NO:31 , SEQ ID NO:27, SEQ ID NO:33, SEQ ID NO:1 3, SEQ ID NO:1 5, SEQ ID NO:39, SEQ ID NO:41 or sequence variants thereof.
  • inventive soluble protein complex may also comprise the amino acid sequences according to SEQ ID NO:1 9, SEQ ID NO:35, SEQ ID NO:27, SEQ ID NO:37, SEQ ID NO:1 9, SEQ ID NO:3, SEQ ID NO:27, SEQ ID NO:31 , SEQ ID NO:27, SEQ ID NO:33, SEQ ID NO:1 3, SEQ ID NO:1 5, SEQ ID NO:39, or e.g.
  • inventive protein complex obtainable by a gene expression system according to the invention may comprise the amino acid sequences according to SEQ ID NO:43, or SEQ ID NO:45, or SEQ ID NO:47, or SEQ ID N049 or sequence variants thereof.
  • the proteins which comprise the amino acid sequences encoding the HCMV glycoproteins gH, gL, pUL128, pUL130 and pUL1 31 or sequence variants thereof, e.g. the amino acid sequences according to SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:1 1, SEQ ID NO:21 and SEQ ID NO:25 are present in equal corresponding amounts in the inventive soluble protein complex, e.g. the relative ratio of e.g. the number (moles) of each of the proteins comprised in the inventive soluble protein complex is an integer, whereby the integer may be e.g. 1 , or e.g. 2, or e.g. 3, or e.g.
  • the inventive soluble protein complex may comprise the proteins, which comprise the amino acid sequences according to SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:1 1 , SEQ ID NO:21 and SEQ ID NO:25 in equal stoichiometric amounts, e.g. the inventive soluble protein complex comprises the HCMV proteins pUL128, pULI 30, pULI 31 , gH and gL in a molar ratio of 1 :1 :1 :1 :1 .
  • the term "molar ratio" as used with the inventive soluble protein complex refers to ratio of moles of each of the proteins comprising the amino acid sequences encoding the HCMV glycoproteins gH, gL, pUL128, pUL130 and pUL131 or sequence variants thereof, e.g. the amino acid sequences according to SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:1 1 , SEQ ID NO:21 and SEQ ID NO:25, e.g. the inventive soluble protein complex comprises the same number of each of the proteins. Accordingly, the inventive soluble protein complex may also comprise equal stoichiometric amounts of e.g.
  • sequence variants of pUL128, pUL130, pUL1 31 , gH and gL such as e.g. SEQ ID NO:3, SEQ ID NO:31 , SEQ ID NO:1 1 , SEQ ID NO:21 and SEQ ID NO:25 or sequence variants thereof, or e.g. SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:33, SEQ ID NO:21 and SEQ ID NO:25 or sequence variants thereof, or e.g. SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:1 1 , SEQ ID NO:35 and SEQ ID NO:25 or sequence variants thereof, or e.g.
  • inventive soluble protein complex as disclosed above is used as a vaccine. Accordingly, the inventive soluble protein complex as described above may be used as a vaccine.
  • the term "vaccine” refers to a formulation which contains the inventive soluble protein complex as disclosed above, which is in a form that is capable of being administered to e.g. a mammal, preferably a human, and which induces an immune response sufficient to induce a therapeutic immunity to prevent, or ameliorate an infection and/or to reduce at least one symptom of an infection and/or to enhance the efficacy of another dose of the inventive soluble protein complex.
  • immune response as used in the context of the inventive use of the soluble protein complex according to the invention refers to both the humoral immune response and the cell-mediated immune response.
  • the humoral immune response involves the stimulation of the production of antibodies by B lymphocytes that, for example, neutralize infectious agents, such as e.g. viruses, e.g. HCMV, block infectious agents from e.g. entering cells, block replication of said infectious agents, and/or protect host cells from infection and destruction.
  • infectious agents such as e.g. viruses, e.g. HCMV
  • the cell-mediated immune response is usually mediated by T- lymphocytes and/or other cells, such as macrophages, against an infectious agent, e.g. viruses such as HCMV, exhibited by a vertebrate (e.g., a human), that prevents or ameliorates infection or reduces at least one symptom thereof.
  • the present invention provides for a vaccine composition, which comprises the inventive soluble protein complex as defined above and optionally one or more pharmaceutically active components.
  • pharmaceutically active component refers to any compound or composition which, when administered to a human or animal induces a desired pharmacologic, immunogenic, and/or physiologic effect by local and/or systemic action.
  • the inventive vaccine composition may comprise optionally an inactive carrier (vaccine excipient), such as e.g. aluminium salts, egg protein, formaldehyde, monosodium glutamate, or e.g. carbohydrates, including, but not limited to, sorbitol, mannitol, starch, sucrose, dextran, glutamate or glucose, or e.g. proteins, including, but not limited to, dried milk, serum albumin, casein.
  • inactive carrier such as e.g. aluminium salts, egg protein, formaldehyde, monosodium glutamate, or e.g. carbohydrates, including, but not limited to, sorbi
  • the vaccine composition according to the invention comprises one or more adjuvants selected from the group comprising mineral salts, surface-active agents, microparticles, cytokines, hormones, antigen constructs, polyanions, polyacrylics, or water-in-oil emulsions.
  • the inventive vaccine composition may comprise one or more, e.g. two, three, four or more adjuvants in addition to the inventive soluble protein complex as disclosed above.
  • adjuvant refers to compounds which, when administered to an individual, such as e.g. a human, or tested in vitro, increase the immune response to an antigen, such as the inventive soluble protein complex, in the individual or test system to which said antigen is administered.
  • an adjuvant typically enhances the immune response of the individual to the antigen (e.g. the inventive soluble protein complex as disclosed above) by rendereing the antigen more strongly immunogenic.
  • the adjuvant effect may also enable the use of a lower the dose of antigen necessary to achieve an immune response in said individual, e.g. a lower dose of the inventive vaccine composition may be required to achieve the desired immune response.
  • the inventive vaccine composition may comprise one or more adjuvants selected from the group comprising mineral salts, surface-active agents, microparticles, cytokines, hormones, antigen constructs, polyanions, polyacrylics, or water-in-oil emulsions.
  • the inventive vaccine composition may comprise one more adjuvants, e.g. one, two, three, four, five, six, seven, eight, nine, or ten or more adjuvants.
  • the inventive vaccine composition may comprise one, two, three, four, five, six, seven, eight, nine, or ten or more adjuvants selected from aluminum (“Alum”), aluminum hydroxide, aluminum phosphate, calcium phosphate, nonionic block polymer surfactants, virosomes, Saponin (QS-21 ), meningococcal outer membrane proteins (Proteosomes), immune stimulating complexes (ISCOMs), Cochleates Dimethyl dioctadecyl ammonium bromide (DDA), Avridine (CP20,961 ), vitamin A, vitamin E, cell wall skeleton of Mycobacterium phlei (Detox®), muramyl dipeptides and tripeptides, Threonyl MDP (SAF-1 ), Butyl-ester MDP (Murabutide®), Dipalmitoyl phosphatidylethanolamine MTP, Monophosphoryl lipid A, Klebsiella pneumonia glycoprotein, Bordetella pertussi
  • liposomes or e.g. biodegradable polymer microspheres, lactide and glycolide, polyphosphazenes, beta-glucan, or e.g. proteinoids.
  • a list of typically used vaccine adjuvants may also be found in e.g. "Vaccine Adjuvants", edited by D.T. O'Hogan, Humana Press 2000.
  • the adjuvant comprised in the inventive vaccine composition may also include e.g.
  • lipid A some of which are TLR-4 agonists, and include, but are not limited to: OM1 74 (2-deoxy-6-o-[2-deoxy-2-[(R)-3-dodecanoyloxytetra-decanoylamino]-4-o-phosphono- D-D-glucopyranosyl]-2-[(R)-3-hydroxy-tetradecanoylamino]-p-D- glucopyranosyldihydrogen- phosphate), (WO 95/14026) OM 294 DP (3S, 9 R) -3 ⁇ [(R)-dodecanoyloxytetradecanoylam, [(R)- 3-hydroxytetradecanoylamino]decan-1 ,10-diol,1 , 10-bis(dihydrogenophosphate) (WO 99/64301 and WO 00/0462) OM 197 MP-Ac DP(3S-,9R)
  • inventive pharmaceutical composition may comprise only one of the above adjuvants, or e.g. two of the above adjuvants, e.g. combination adjuvants such as e.g. Alum and MPL, or Oil-in-water emulsion and MPL and QS-21 , or liposomes and MPL and QS21 .
  • combination adjuvants such as e.g. Alum and MPL, or Oil-in-water emulsion and MPL and QS-21 , or liposomes and MPL and QS21 .
  • the vaccine composition according to the invention comprises an adjuvant selected from the group comprising Alum, Ribi (Monophosphoryl lipid A, MPL), or MF59.
  • the inventive vaccine composition may comprise Alum, or Ribi (Monophosphoryl lipid A, MPL), or MF59, or e.g. Alum and Ribi, or e.g. Alum and MF59, or e.g. Ribi and MF59.
  • the inventive vaccine composition may be formulated as a liquid formulation, or alternatively and as a preferred embodiment as a lyophilized formulation.
  • liquid formulation refers to a water-based formulation, in particular, a formulation that is an aqueous solution.
  • the liquid composition may e.g. further comprise ethanol, or e.g. non-ionic detergents, or e.g. anti-oxidants, such as oxygen scavengers to prevent oxidation of the inventive vaccine composition, e.g. vitamin E, or e.g. vitamin C.
  • the water for use with the inventive liquid vaccine composition may e.g. be USP-grade water for injection.
  • the inventive liquid vaccine composition formulation may for example also consist of, or comprise an emulsion.
  • An emulsion comprises a liquid suspended in another liquid, typically with the aid of an emulsifier.
  • the inventive liquid vaccine composition may also e.g. be a microemulsion, which is a thermodynamically stable solution that is clear upon visual inspection.
  • the inventive vaccine composition may be provided as a lyophilized formulation.
  • lyophilized formulation as used with the inventive vaccine composition means a freeze- dried formulation prepared by the processes known in the art, such as e.g. those provided in "Cryopreservation and Freeze-Drying Protocols” (2007), JG Day, GN Stacey (eds)., Springer, ISBN 978-1 -58829-377-0, and comprising as essential ingredient the soluble protein complex according to the invention.
  • the inventive vaccine composition may comprise a buffer selected from the group of phosphate buffer, Na-acetate buffer, Tris buffer, MOPS buffer, preferably the buffer is a phosphate buffer.
  • the inventive vaccine composition may comprise a phosphate buffer, or a Na-acetate buffer, or a Tris buffer, or a MOPS buffer, preferably the inventive vaccine composition comprises a phosphate buffer.
  • the inventive vaccine composition may comprise a a Na-acetate buffer in a concentration of about 0.1 mM to about 500mM, or of about 1 mM to about 250mM, or of about 10mM to about 125mM, or of about 25mM to about 10OmM, or of about 50mM to about 75 mM, or of about 60 mM to about 70 mM, or of about 7.5 mM, 10 mM, 12.5 mM, 15 mM, 20 mM, 22.5 mM, 25 mM, 27.5 mM, 30 mM, 32.5 mM, 35 mM, 40 mM, 45 mM, 50 mM, 55 mM, 60 mM, 65 mM, 70 mM, 75 m
  • the inventive vaccine composition may also comprise a Tris buffer (tris(hydroxymethyl)aminomethane ), in the above concentrations, or e.g. a 3-(N- morpholino)propanesulfonic acid) (MPOS) buffer in the above concentrations, or e.g. a (4-(2- hydroxyethyl)-1 -piperazineethanesulfonic acid ) (HEPES) buffer in the above concentrations, or e.g. a 2-(N-morpholino)ethanesulfonic acid (MES) buffer in the above concentrations, or e.g. a N-cyclohexyl-3-aminopropanesulfonic acid (CAPS) buffer in the above concentrations.
  • a Tris buffer tris(hydroxymethyl)aminomethane
  • MPOS 3-(N- morpholino)propanesulfonic acid)
  • HEPES 4-(2- hydroxyethyl)-1 -piperazineethanesulf
  • the inventive vaccine composition comprises a phosphate buffer.
  • the total phosphate concentrations for the buffer may be from about 5 mM to about 500 mM, or from about 7.5 mM, 10 mM, 12.5 mM, 1 5 mM, 20 mM, 22.5 mM, 25 mM, 27.5 mM, 30 mM, 32.5 mM, 35 mM, 40 mM, 45 mM, 50 mM, 55 mM, 60 mM, 65 mM, 70 mM, 75 mM, 80 mM, 85 mM, 90 mM, 95 mM, 100 mM to about 125 mM, 1 30 mM, 1 35mM, 1 37 mM, 140 mM, 145 mM, 1 50 mM, 1 55 mM, 1 60 mM, 1 65 mM, 1 70 mM, 1 75 mM, 1 80 mM, 1 85
  • the inventive vaccine composition may also comprise PBS as phosphate buffer, which comprises 1 37 mM NaCI, 2.7 mM KCI, 10 mM Na 2 HP0 4 and 1 .8 mM KH 2 P0 4 , or e.g. NaCl in a concentration of about 1 58 mM.
  • PBS phosphate buffer
  • the inventive vaccine composition is buffered by the buffer at a pH range of about pH 7-9, preferably of about pH 7.5 to about pH 8.8, or of about pH 7.8 to about pH 8.6, or of about pH 8.0 to about pH 8.4.
  • the inventive vaccine composition is buffered by a buffer as disclosed above, e.g. by a Tris buffer, MOPS buffer, Na-acetate buffer, or phosphate buffer in concentrations as disclosed above.
  • the inventive vaccine composition may be buffered at a pH range of about pH 7-9, e.g.
  • the vaccine composition according to the invention may also comprise a preservative.
  • preservative as used in the present invention shall mean any compound that when added to the inventive vaccine composition prolongs the time the inventive vaccine composition may be stored prior to use.
  • Preservatives included with the inventive vaccine composition may include e.g. albumin, phenols, glycine, Thimerosal, benzalkonium chloride, polyaminopropyl biguanide, phenoxyethanol, merthiolate, gentamicin, neomycin, nystatin, amphotericin B, tetracycline, penicillin, streptomycin, polymyxin B, and any combination thereof.
  • the inventive vaccine composition may comprise any of the above compounds in a concentration of about 0.001 % (w/v)/(w/w) to about 5% (w/v)/(w/w), or of about 0.02% (w/v)/(w/w), 0.03% (w/v)/(w/w), 0.04 % (w/v)/(w/w), 0.05% (w/v)/(w/w), 0.06% (w/v)/(w/w), 0.07% (w/v)/(w/w), 0.08% (w/v)/(w/w), 0.09% (w/v)/(w/w), 0.1 % (w/v)/(w/w) to about 0.2 % (w/v)/(w/w), 0.25 % (w/v)/(w/w), 0.3 % (w/v)/(w/w), 0.4 % (w/v)/(w/w), 0.5% (w/v)/(w/w/
  • the inventive vaccine composition as disclosed above is for use in the vaccination of humans.
  • the term "vaccination" as used in the context of the inventive vaccine composition refers to the administration of antigenic material, such as e.g. the inventive vaccine composition (a vaccine), to stimulate an individual's immune system to develop develop an adaptive immune response to a pathogen, such as HCMV in order to prevent, or reduce the risk of infection.
  • the inventive vaccine or inventive vaccine composition will be administered to a human in a dose suitable to induce a sufficient immune response, e.g. an immune response that comprises T- and B-cell memory and neutralizing antibodies to provide protective immunity against a pathogen that comprises one or more proteins or protein complexes that comprise at least one, e.g.
  • amino acid sequences as disclosed above e.g. UL128, UL130, UL131 , gH and gL , or e.g. sequence variants thereof, such as e.g. SEQ ID NO:3, SEQ ID NO:31 , SEQ ID NO:1 1 , SEQ ID NO:21 and SEQ ID NO:25 or sequence variants thereof, or e.g. SEQ ID NO:3, SEQ ID NO:7, SEQ ID NO:33, SEQ ID NO:21 and SEQ ID NO:25 or sequence variants thereof, or e.g.
  • the present invention provides a process for the preparation of a vaccine according to the disclosure as provided herein.
  • the present invention provides for a process of the preparation of an inventive vaccine, which may e.g. comprise the steps of (i) using the inventive gene expression system as disclosed above for the expression of a soluble protein complex as disclosed above, (ii) purifying the inventive soluble protein complex obtainable by the inventive gene expression system, (iii) preparing a vaccine composition as disclosed above.
  • step (i) may include culturing the at least one mammalian cell as defined above, such as e.g.
  • the purification step (ii) may e.g. employ affinity chromatography utilizing the Strep-tag technology, if at least one of the proteins of the inventive soluble protein complex comprises the amino acid sequence according to SEQ IDNO:1 7 and/or SEQ ID NO:39, or SEQ ID NO:1 7 and SEQ ID NO:39, or e.g. the purification step may require purification by means of Nickle-NTA agarose, if at least one of the proteins of the inventive soluble protein complex comprises the amino acid sequence according to SEQ ID NO:1 3 and SEQ ID NO:41 (6x His-tagged TEV), or SEQ ID NO:41 (6xHis tag).
  • Protocols for purification of soluble protein complexes are known in the art.
  • the purification of an inventive soluble protein complex as disclosed above may be done according to the method as described by Alsarraf et al, Acta Crystallogr Sect F Struct Biol Cryst Commun. Oct 1 , 201 1 ; 67(Pt 10): 1253- 1256, e.g. the cell culture medium may be incubated with e.g. 20 ml NTA agarose beads (Qiagen; pre-equilibrated with buffer A) for 1 h. The beads may then e.g.
  • buffer B 50 mM Tris-HCl pH 8, 1 M NaCl, 50 mM imidazole, 5 mM ⁇ - mercaptoethanol and 1 mM benzamidine
  • the protein may then e.g. be eluted with buffer E (50mM Tris-HCl pH 8, 400 mM NaCl, 500 mM imidazole and 5 mM ⁇ -mercaptoethanol).
  • the eluted protein may then e.g. be dialyzed in dialysis bags (cutoff e.g. 5 kDa) overnight at 277 K against 21 anion-exchange buffer (50 mM Tris- HCl pH 8 and 5 mM ⁇ -mercaptoethanol).
  • the proteins may e.g. be spun down at 30 OOOg for 1 0 min to remove protein aggregates.
  • the supernatant may then e.g. be loaded onto a 2 x 5 ml Hi-Trap Q-FF anion-exchange column (GE Healthcare Life Sciences) equilibrated with anion-exchange buffer and the protein may be collected in the flowthrough (while the rest of the contaminants bound to the column).
  • the inventive soluble protein complex may then be concentrated to 1 mg ml/ml and dialyzed against storage buffer (e.g. 50 mM Tris-HCI pH 7.6, 5 mM ⁇ -mercaptoethanol and 50% glycerol).
  • inventive soluble protein complex comprising SEQ ID NO:13 or sequence variants thereof may also be further purified by treatment with TEV protease and e.g. subsequent dialysis as disclosed above, e.g. the inventive soluble protein complex comprising SEQ ID NO:13 or sequence variants thereof may be incubated with TEV protease e.g. for about 1 h, 2h, 3h, 4h, 5h, 6h, or for about 6h to about 12h, and subsequently dialyzed or e.g.
  • the inventive soluble protein complex as disclosed above comprising SEQ ID NO:1 3 and SEQ ID NO:41 or sequence variants thereof, wherein the 6xHis tag as according to amino acid sequence according to SEQ ID NO:41 or sequence variants thereof is located C- terminally, e.g. ENLYFQG-HHHHHH- and linked via a peptide bond to the TEV cleave site, may be purified in a first step as disclosed above, e.g. by a metal -affinity resin, such as e.g. Nickel- NTA, followed by subsequent incubation with TEV protease treatment and a further metal-affinity resin purification step to remove the cleaved TEV-6xHis-tag fragments.
  • the purified soluble protein complex may then e.g. be recovered from the flow-through.
  • the present invention provides for a nucleic acid comprising SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:22, and SEQ ID NO:26 or sequence variants thereof, or SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:8, SEQ ID NO:12, SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:14, SEQ ID NO:1 6 and SEQ ID NO:42 or sequence variants thereof.
  • the inventive nucleic acid may comprise the above sequences in any order, for as long as the nucleic acid can be used to transfect, or nucleofect mammalian cells as disclosed above, to obtain the inventive soluble protein complex.
  • the inventive nucleic acid sequence further comprises SEQ ID NO:6 and/or SEQ ID NO:10 and/or SEQ ID NO:24, and/or SEQ ID NO:28, and/or SEQ ID NO:30, preferably comprising SEQ ID NO:24 and/or SEQ ID NO:28 and/or SEQ ID NO:30 or sequence variants thereof.
  • the inventive nucleic acid may comprise e.g. SEQ ID NO:6 or SEQ ID NO:10 or SEQ ID NO:24, or SEQ ID NO:28, or SEQ ID NO:30 or sequence variants thereof, or e.g. SEQ ID NO:6 and SEQ ID NO:10 or sequence variants thereof, or e.g.
  • the inventive nucleic acid comprises SEQ ID NO:24 and/or SEQ ID NO:28 and/or SEQ ID NO:30 or sequence variants thereof, e.g. SEQ ID NO:24 or SEQ ID NO:28 or SEQ ID NO:30 or sequence variants thereof, or e.g. SEQ ID NO:24 and SEQ IDNO:28 or sequence variants thereof, or e.g. SEQ ID NO:24 and SEQ ID NO:30 or sequence variants thereof, or e.g. SEQ ID NO:28 and SEQ ID NO:30 or sequence variants thereof, or e.g. SEQ ID NO:24 and SEQ ID NO:28 and SEQ ID NO:30 or sequence variants thereof, or e.g. SEQ ID NO:24 and SEQ ID NO:28 and SEQ ID NO:30 or sequence variants thereof.
  • inventive nucleic acid may comprise operably linked in 5' to 3' direction the nucleotide sequences according to SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:1 6, SEQ ID NO:1 8, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24 and SEQ ID NO:26 or sequence variants thereof.
  • operably linked refers to nucleic acid which are juxtaposed in such a way that their respective functions are mutually dependent.
  • a promoter operably linked to a coding sequence is capable of effecting the expression of the coding sequence.
  • the term "operably linked" may also be independent of the location a respective sequence, as long as the functional interrelationship between the two sequences is maintained, e.g. the nucleotide sequences as disclosed above may not be adjacent next to each other in 5'-3' direction, but may e.g. be separated by nucleotide sequences of undefined length.
  • the inventive nucleic acid comprises the above nucleotide sequences in any given order operably linked in 5' to 3' direction, for as long as the inventive nucleotide sequence encodes the soluble protein complex according to the invention, e.g. the inventive nucleic acid comprises operably linked in 5' to 3' direction the nucleotide sequences according to SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:10, SEQ ID NO:8, SEQ ID NO:6, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:1 6, SEQ ID NO:1 8, SEQ ID NO:20, SEQ ID NO:26, SEQ ID NO:24 and SEQ ID NO:22 or sequence variants thereof, or e.g.
  • SEQ ID NO:2 SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:14, SEQ ID NO:1 6, SEQ ID NO:1 8, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:24 and SEQ ID NO:26 or sequence variants thereof, or e.g.
  • the inventive nucleic acid comprises operably linked in 5' to 3' direction the nucleotide sequences according to SEQ ID NO:20, SEQ ID NO:4, SEQ ID NO:28, SEQ ID NO:32, SEQ ID NO:28, SEQ ID NO:34, SEQ ID NO:20, SEQ ID NO:36, SEQ ID NO:28 and SEQ ID NO:38 or sequence variants thereof.
  • the inventive nucleic acid comprises the above nucleotide sequences in any given order operably linked in 5' to 3' direction, for as long as the inventive nucleic acid encodes the soluble protein complex according to the invention, e.g.
  • the inventive nucleic acid comprises operably linked in 5' to 3' direction the nucleotide sequences according to SEQ ID NO:20, SEQ ID NO:36, SEQ ID NO:28 and SEQ ID NO:38, SEQ ID NO:20, SEQ ID NO:4, SEQ ID NO:28, SEQ ID NO:32, SEQ ID NO:28, SEQ ID NO:34 or sequence variants thereof, or e.g. SEQ ID NO:20, SEQ ID NO:38, SEQ ID NO:28 and SEQ ID NO:36, SEQ ID NO:20, SEQ ID NO:4, SEQ ID NO:28, SEQ ID NO:32, SEQ ID NO:28, SEQ ID NO:34 or sequence variants thereof, or .e.g.
  • inventive nucleic acid may comprise operably linked in 5' to 3' direction the nucleotide sequences according to SEQ ID NO:20, SEQ ID NO:4, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:20, SEQ ID NO:36, SEQ ID NO:30 and SEQ ID NO:38 or sequence variants thereof, or e.g.
  • inventive nucleic acid may comprise operably linked in 5' to 3' direction SEQ ID NO:20, SEQ ID NO:4, SEQ ID NO:28, SEQ ID NO:32, SEQ ID NO:28, SEQ ID NO:34, SEQ ID NO:14, SEQ ID NO:1 6, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:20, SEQ ID NO:36, SEQ ID NO:28 and SEQ ID NO:38 or sequence variants thereof, or e.g.
  • inventive nucleic acid may comprise operably linked in 5' to 3' direction SEQ ID NO:20, SEQ ID NO:4, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:14, SEQ ID NO:1 6, SEQ ID NO:40, SEQ ID NO:42, SEQ ID NO:20, SEQ ID NO:36, SEQ ID NO:30 and SEQ ID NO:38, or e.g.
  • inventive nucleic acid comprises operably linked in 5' to 3' direction SEQ ID NO:20, SEQ ID NO:4, SEQ ID NO:28, SEQ ID NO:32, SEQ ID NO:28, SEQ ID NO:34, SEQ ID NO:14, SEQ ID NO:1 6, SEQ ID NO:40, SEQ ID NO:20, SEQ ID NO:36, SEQ ID NO:28 and SEQ ID NO:38 or sequence variants thereof, or e.g.
  • inventive nucleic acid may comprise operably linked in 5' to 3' direction SEQ ID NO:20, SEQ ID NO:4, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:30, SEQ ID NO:34, SEQ ID NO:14, SEQ ID NO:16, SEQ ID NO:40, SEQ ID NO:20, SEQ ID NO:36, SEQ ID NO:30 and SEQ ID NO:38 or sequence variants thereof, or e.g.
  • the inventive nucleic acid comprises the nucleotide sequence according to SEQ ID NO:44, or SEQ ID NO:46, or SEQ ID NO:48, or SEQ ID NO:50 or sequence variants thereof.
  • the inventive nucleic acid comprising the nucleotide sequence according to SEQ ID NO:44 or sequence variants thereof encodes the amino acid sequence of the inventive soluble protein complex comprising the amino acid sequence according to SEQ ID NO:43 or sequence variants thereof, or e.g.
  • the inventive nucleic acid comprising the nucleotide sequence according to SEQ ID NO:46 or sequence variants thereof encodes the amino acid sequence of the inventive soluble protein complex comprising the amino acid sequence according to SEQ ID NO:45 or sequence variants thereof, or e.g. the inventive nucleic acid comprising the nucleotide sequence according to SEQ ID NO:48 or sequence variants thereof encodes the amino acid sequence of the inventive soluble protein complex comprising the amino acid sequence according to SEQ ID NO:47 or sequence variants thereof, or e.g.
  • the inventive nucleic acid comprising the nucleotide sequence according to SEQ ID NO:50 or sequence variants thereof encodes the amino acid sequence of the inventive soluble protein complex comprising the amino acid sequence according to SEQ ID NO:49 or sequence variants thereof.
  • the invention provides for a nucleic acid as disclosed above for use in a process according to any one of the above embodiments, e.g. for use in the inventive gene expression system, or e.g. to obtain the inventive soluble protein complex as disclosed above, or e.g. in a process to obtain the inventive vaccine composition as disclosed above.
  • the present invention provides for a mammalian cell comprising at least one nucleic acid according to the present invention for use in a process according to the present invention.
  • the present invention provides for a CHO cell, which comprises at least one inventive nucleic acid as disclosed above for use in a process for the preparation of a vaccine according to the invention.
  • CHO cell refers to any cell selected from CHO-DG44, CHO-K1 , CHO-K1 SV, CHO- S, CHO-DXB1 1 , or CHO-K1 SV GS knock-out (CHO-K1 SV KO) cell types.
  • the term CHO cell as used also includes at least one CHO cell as disclosed above, e.g.
  • CHO cell refers to at least 1 , or at least 10, or at least 100, or at least 1000, or at least about 10,000 cells, or of at least about 10 5 , 10 6 , 107, 10 8 , 10 9 , 10 10 , 10 11 , 10 12 CHO cells as disclosed above, or e.g. if the CHO cells are grown in a non-adherent culture of about 10 3 cells/ml, or of about 10 4 cells/ml, to about 10 9 cells/ml, e.g.
  • the CHO cell comprising at least one nucleic acid according to the present invention may e.g. comprise 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 10 2 , 10 3 , 1 0 4 nucleic acids according to the invention, or e.g. of about 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10 inventive nucleic acid molecules to about 10 2 , 10 3 inventive nucleic acid molecules, e.g. expression vectors.
  • the expression vector may be any of e.g. a viral vector selected from the group consisting of a plasmid or an adeno-associated virus, a retrovirus, a vaccinia virus, an oncolytic adenovirus, and the like, or e.g. a as comprised in the inventive gene expression system, e.g. such as those disclosed in the appended examples.
  • the present invention provides for a kit of parts, which comprises the inventive gene expression system as disclosed above. Accordingly, the present invention provides for, or relates to a kit, such as a kit of parts, that includes a plurality of components for the construction and/or use of the inventive gene expression system.
  • the kit of parts according to the invention may comprise at least two components that include (preferably separately): (i) a vector comprising the inventive transcription system, and (ii) at least one other component for the use of the inventive gene expression system, such as e.g. at least one mammalian cell, e.g. preferably at least one CHO cell as defined above and (iii) optionally reagents, such as e.g.
  • reagents for the transfection of the at least one mammalian cell comprised in the kit with the inventive nucleic acid may include e.g. liposomal transfection agents, or non-liposomal transfection agents, such as FuGene ® or Lipofectamine 2000 ® transfection reagents.
  • the vector comprised in the inventive kit of parts may e.g. be provided as an ethanolic precipitate, lyophilized and may be provided in an amount e.g. about 1 pg to about 100 pg, or e.g. in an amount of e.g. 10 pg to about 50 pg, or in an amount of about 25 pg to about 75 pg, e.g.
  • the inventive kit of parts may e.g. also comprise as second (ii) component at least one mammalian cell as defined above, such as e.g. CHO cells as defined above, which have been transfected with the inventive nucleic acid.
  • the at least one mammalian cell may e.g. also be provided in a suitable culture medium, such as e.g.
  • Freestyle® CHO expression medium or ProCHOTM medium, or PowerCHOTM, or UltraCHOTM, or any other culture medium suited for the expression of the HCMV surface glycoproteins according to the invention.
  • the culture medium may, however, also form a separate part of the inventive kit of parts.
  • the plurality of components in the inventive kit may be presented, packaged or stored separately.
  • the components of the inventive kit of parts may be isolated from one another by being held in separate containers, e.g. such components, although held separately, may be boxed or otherwise associated together to aid storage and/or transport, and such association may include additional components.
  • transfection refers to the uptake of foreign DNA by a cell, e.g. by the at least one mammalian cell as disclosed above. Accordingly, a cell has been "transfected" when exogenous DNA, such as any one of the inventive nucleic acids as disclosed above, has been introduced into a cell.
  • transfection techniques are generally known in the art, see, e.g., Graham et al. (1 973) Virology, 52:456, or Green et al. "Molecular Cloning - a laboratory manual” CSH Laboratory Press, 2012, or Davis et al. (1986) Basic Methods in Molecular Biology, Elsevier, and Chu et al. (1981 ) Gene 13 :197.
  • Such techniques can be used to introduce one or more exogenous DNA moieties into suitable host cells.
  • the term refers to both stable and transient uptake of the genetic material e.g. of the inventive nucleic acid, and includes uptake of peptide- or antibody-linked DNAs.
  • the inventive vector comprising a transcription system as disclosed above refers to an assembly which is capable of directing the expression of a one or more sequences or genes of interest.
  • the inventive nucleic acid expression vector includes one or more promoters, e.g. two, three, four or more promoters, which are operably linked to the nucleotide sequences according to the invention and optional ly to additonal gene(s) of interest. For example, other control elements may be present on the vector as well.
  • the inventive vector as disclosed above may e.g. also comprise and in addition to the components of the transcripton system, a bacterial origin of replication, and e.g. one or more selectable markers, such as e.g.
  • the vector may further comprise e.g. a signal which allows the plasmid construct to exist as single-stranded DNA (e.g., a Ml 3 origin of replication), a multiple cloning site, and a "mammalian" origin of replication (e.g., a SV40 or adenovirus origin of replication).
  • a signal which allows the plasmid construct to exist as single-stranded DNA e.g., a Ml 3 origin of replication
  • a multiple cloning site e.g., a multiple cloning site
  • a "mammalian" origin of replication e.g., a SV40 or adenovirus origin of replication
  • the present invention relates to a method of vaccinating a human, wherein the method comprises administering to a person the inventive vaccine composition as disclosed above in therapeutically effective amounts. Accordingly, the present invention relates to a method of administering to a person a therapeutically effective amount of the i nventive vaccine composition as disclosed above.
  • therapeutic ly effective amount means an amount of the inventive vaccine composition administered which is of sufficient quantity to achieve the intended purpose, e.g. to induced a protective immune response, involving e.g. both innate and adaptive immune responses.
  • the inventive method of vaccinating a human may comprise providing the inventive vaccine or vaccine composition as disclosed above to a human, e.g.
  • the inventive vaccine or vaccine composition as disclosed above may be administered oral ly (p.o.), or e.g. intravenously (i.v.), or intra muscular (i.m.), or e.g. transdermal ly, or e.g. via inhalation, or e.g. subcutaneously, e.g. by i njection or by a particle del ivery system, such as a gene gun.
  • the vaccine may e.g. be comprised in or on the particles delivered by the gene gun.
  • the inventive method of vacci nation may comprise administeri ng to a human about 0.2 to about 200 g, or about 2 ⁇ g to about 1 50 g, or about 5 g- to about 1 00pg, or about 1 0pg to about 90 g, or about 1 5 to about 80 g of the vaccine composition according to the invention as disclosed above.
  • the inventive method of vaccination comprises administering to a human about 0 ⁇ g to about 200 g of the inventive vaccine composition, e.g. about 0.5 g to about 1 95 or e.g. about 1 ⁇ g to about 1 90 g, or e.g. about 1 .5 ⁇ g to about 1 85 ⁇ g, or e.g.
  • inventive soluble protein complex refers to the amount of the inventive soluble protein complex in the inventive vaccine or vaccine composition, or e.g. to the total amount of the inventive vaccine or vaccine composition administered, e.g. the inventive soluble protein complex, one or more adjuvants and/or one or more pharmaceutically active components as disclosed above.
  • the inventive method of vaccination may comprise administering the inventive vaccine composition or vaccine to a human at least once, twice or three times.
  • the inventive vaccine composition or vaccine as disclosed above may be administered in any amount as disclosed above, following e.g. any vaccination schedule for a 2 or 3 or more dose vaccination, for example a 0, 1 month schedule, a 0, 2 month schedule, a 0, 3 month schedule, a 0, 4 month schedule, a 0, 5 month schedule or a 0, 6 month schedule for a 2 dose vaccine; a 0, 1 6 month schedule, a 0, 2, 6 month schedule, a 0, 3, 6 month schedule, a 0,4, 6 schedule for a 3 dose vaccination.
  • the second dose may e.g. be administered one month, or e.g. two months, or e.g.
  • a third dose may e.g. be administered one month, or e.g. two months, or e.g. three months, or e.g. four months, or e.g. five months, or e.g. six months, or e.g. up to twelve months, or e.g. up to twenty-four months after the second dose.
  • the inventive vaccine composition as disclosed above may be e.g. administered subcutaneously, e.g. in any amount as disclosed above and according to any vaccination schedule, e.g. according to a vaccination schedule as disclosed above.
  • the term "subcutaneous" or “subcutaneously” as used with the inventive method refers to an injection, or delivery of the inventive vaccine or vaccine composition to the layer of skin directly below the dermis and epidermis, which is also collectively referred to as cutis.
  • the subcutaneous administration may be done by any appropriate means, such as e.g. a needle, or e.g. single use injection devices, or e.g. needle-free injection devices such as e.g. BiojectTM, ZetajetTM injection devices.
  • the inventive vaccine composition as disclosed above is administered intra-muscularly (i.m.), e.g. in any amount as disclosed above and according to any vaccination schedule, e.g. according to a vaccination schedule as disclosed above.
  • intra-muscular or “intra-muscularly” as used with the inventive method refers to an injection, or delivery of the inventive vaccine or vaccine composition refers to the injection of a substance directly into a muscle, e.g. preferably to an injection of the inventive vaccine or vaccine composition into a muscle of e.g. the upper thigh, or e.g. vastus lateralis, vastus medialis, or e.g. vastus intermedius muscle, or e.g.
  • the intra muscular administration may be done by any appropriate means, such as e.g. an injection device, such as e.g. a syringe, or e.g. single use injection devices, e.g. single-use injection syringes.
  • the single-use injection syringes, or single-use injection devices may comprise, pre- filled, a single dose of the inventive vaccine or vaccine composition as disclosed above, in an amount as disclosed above, e.g.
  • inventive vaccine or vaccine composition may e.g. be provided in different doses as may be required for the vaccination of newborns, infants or adults, e.g. in lower or larger amounts.
  • inventive vaccine or inventive vaccine composition as disclosed above may also be administered in combination with one or more HCMV vaccines, e.g. the inventive vaccine or vaccine composition may be administered in combination with e.g. one or more vaccines selected from the group comprising e.g. gB, or e.g. gB-based vaccines, or HCMV vaccines comprising the AD1 69 HCMV strain(cf. e.g. Neff et al. (1 979) Proc Soc Exp Biol Med, 1 60:32- 7), or e.g.
  • the inventive vaccine or vaccine composition may thus be administered as e.g. an admixture of the inventive vaccine or vaccine composition with one or more of the above HCMV vaccines, e.g.
  • inventive vaccine or inventive vaccine composition may e.g. be administered e.g. prior to, or e.g. concurrent with, or e.g. subsequent, with one of the HCMV vaccines as disclosed above, for example, the inventive vaccine or vaccine composition may be e.g. administered 6 months, or e.g. 3 months, or e.g. 1 month, or e.g. 14 days or e.g.
  • the term "in combination" as used in the present invention for the administration of the inventive vaccine may e.g. also refer to the separate administration of one of the vaccines as disclosed above with regard to the inventive vaccine, e.g. the term administered in combination may comprise a first administration of the inventive vaccine and a separate, e.g. later administration of one or more vaccines as disclosed above, or the term may also refer to a first administration of a HCMV vaccine as disclosed above, followed by an administration of the inventive vaccine, according to any vaccination schedule as disclosed above.
  • the genes encoding the five subunits of the HCMV pentameric complex (gH, gl_, pUL128, pUL130 and pUL1 31 ) were engineered and cloned into a unique vector. Expression of the genes encoding gH and gL was driven by a first human CMV promoter. The genes were separated by a sequence encoding the self-processing peptide P2A of the Foot-and- Mouth Disease virus.
  • the gH gene was deleted of the transmembrane and cytoplasmic domains. Expression of UL128, UL130 and UL131 was driven by a second human CMV promoter. Genes encoding the self-processing peptide T2A and F2A of the Foot-and- Mouth Disease virus were inserted between UL128 and UL130 and UL1 30 and UL1 31 , respectively.
  • the DNA construct according to Example 1 was used to produce a stable cell line producing a soluble HCMV pentameric complex.
  • CHO-K1 SV line (GS-system, licensed by IRB from Lonza) were nucleofected with the prepared vector. Stably transfected CHO clones were obtained. The best clone was further sub-cloned to get a stable line with high level production of HCMV pentameric complex.
  • the product of these cell line was characterized ( Figure 3).
  • the preparation of purified, tag-free, HCMV pentameric complex was monodisperse with no signs of aggregation (panel a, b). Secondary structure analysis by circular dichroism revealed that the complex was mainly oc-helical and possessed a high stability (Tm ⁇ 60°C), as measured by thermal denaturation analysis (panel c, d).
  • the correct folding of the soluble HCMV pentameric complex was assessed by ELISA using a large panel of human monoclonal antibodies directed against different epitopes displayed on the complex. Antibodies specific for epitopes requiring a combination pULl 30 and pUL131 or all 5 proteins present in the HCMV pentameric complex (i.e. gH, gL, pUL128, pUL1 30 and pUL1 31 ) reacted with the soluble HCMV pentameric complex produced by the selected CHO cell clone.
  • a neutralization assay of HCMV was performed using the epithelial cell lines ARPE 1 9 as target and either a monoclonal human anti-HCMV antibody (5A2) as control or the soluble HCMV pentameric complex (Figure 4).
  • the antibody was pre-incubated with the virus for 1 h at 37°C before addition to the target cells while the complex was pre-incubated with the target cells for 1 h at 37°C before addition of the virus. Both the antibody and the soluble complex interfere with virus entry, with IC50 of 0.13 nM or 1 .9 nM, respectively.
  • This data further supports the concept that the soluble HCMV pentameric complex has the correct folding capable of binding to the cellular receptor used by the virus to infect target cells.
  • HCMV pentameric complex produced as in Example 2 was assessed by immunizing Balb/c mice subcutaneously into flank on day 0. Two booster immunization were given on day +14 and day +28. Sera were analyzed on day +40. Dose-finding experiments showed that high serum binding titers to gHgL or gHgLpULI 28L were induced at doses as low as 1 pg/mouse ( Figure 5a, b). Extraordinarily high serum neutralizing titers of HCMV infection of epithelial cells were induced at a dose of 5 pg/mouse and 2.5 pg/mouse.
  • mice were immunized 40 days before with 0.2 pg pentamer had neutralizing titers that inhibited infection of both epithelial cells or fibroblasts significantly higher to those found in the sera of patients 1 months after HCMV infection ( Figure 5d).
  • mice were immunized with the HCMV pentameric complex (2.5 pg/mouse) formulated in three different clinically used adjuvants: Alum, MF59, and Ribi. When normalized on total IgG serum content, the three preparations were equally effective in inducing high serum binding and neutralizing titers (Figure 6).
  • the HCMV pentameric complex vaccine elicits an antibody response of high specific activity
  • memory B cells from immunized mice were fused with myeloma cells and monoclonal antibodies were isolated from hybridomas.
  • Three hundreds forty two 342 monoclonal antibodies that bound to soluble gB were obtained from 4 gB-vaccinated mice, while 247 monoclonal antibodies that bound to the soluble HCMV pentameric complex were obtained from 4 complex-vaccinated mice ( Figure 7a).).
  • the HCMV pentameric complex vaccine preferentially elicit neutralizing antibodies and has therefore a higher specific activity than the gB vaccine.
  • the HCMV pentameric complex vaccine elicits a broad repertoire of antibodies neutralizing infection of both fibroblasts as well as epithelial, endothelial, and myeloid cells
  • the fine specificity and functional properties of the monoclonal antibodies isolated from mice immunized with the HCMV pentameric vaccine was studied using binding and neutralization assays.
  • a large fraction of the antibodies (67%) was specific for gHgL, since they bound to both gHgL dimer and gHgl_pUL128L pentameric complexes and neutralized infection of both fibroblasts and epithelial cells, with IC80 values in the nanomolar range (IC80 0.5-10 nM).
  • mice A side-to-side comparison showed that mouse antibodies elicited by the HCMV pentameric complex vaccine and human antibodies induced by natural HCMV infection had comparable potencies and fine specificities, as determined by their capacity to bind to cells transfected with gH, gl_ UL128, UL1 30, and UL131 genes in different combinations.
  • cross- competition experiments showed that some of the most potent neutralizing antibodies produced by vaccinated mice targeted novel antigenic sites on the pentamer that were not identified using the large panel of human monoclonal antibodies previously isolated (Table 1 / Figure 5).
  • the above findings demonstrate that the gHgLpUL128L pentameric vaccine can elicit a strong antibody response that is largely composed of potent neutralizing antibodies that inhibit HCMV infection of fibroblasts, epithelial, endothelial, and myeloid I cells similar to those produced in humans in HCMV infection.
  • Mouse monoclonal antibodies (m-Abs) and human monoclonal antibodies (h-Abs) are grouped according to their ability to neutralize HCMV infection of epithelial cells only or epithelial cells and fibroblasts. Shown are the log IC80 values, corresponding to the concentration that inhibits 80% infection.
  • Ab target antigen was determined using HEK293T cells transfected with different combination of HCMV genes.
  • Cross-competition ELISA assays were performed to identify the m- Abs binding to overlapping sites bound by a panel of human monoclonal antibodies previously isolated (Macagno et al, J Virol. 2010 Jan;84(2):1005-13. doi: 10.1 128/JVI.01809-09).

Abstract

La présente invention concerne un vecteur et un système d'expression génique permettant de produire un complexe soluble de protéine pentamère comprenant les glycoprotéines du cytomégalovirus humain (HCMV) UL128, UL1 30, UL131, gH et gl_ ou de ses variantes de séquence, ainsi que des compositions de vaccin les comprenant. La présente invention concerne en outre une composition de vaccin pour une utilisation dans la vaccination prophylactique ou thérapeutique contre des infections par HCMV. L'invention concerne également des procédés de production du vaccin selon l'invention. En outre, la présente invention se rapporte à des méthodes de vaccination d'êtres humains avec la composition de vaccin de l'invention.
PCT/EP2014/001168 2014-04-23 2014-04-30 Compositions de vaccin de cytomégalovirus humain et leur procédé de production WO2015165480A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PCT/EP2014/001168 WO2015165480A1 (fr) 2014-04-30 2014-04-30 Compositions de vaccin de cytomégalovirus humain et leur procédé de production
PCT/EP2015/000843 WO2015161926A1 (fr) 2014-04-23 2015-04-23 Compositions de vaccin contre le cytomégalovirus humain et méthode de production associée
AU2015251221A AU2015251221A1 (en) 2014-04-23 2015-04-23 Human cytomegalovirus vaccine compositions and method of producing the same
CA2944230A CA2944230A1 (fr) 2014-04-23 2015-04-23 Compositions de vaccin contre le cytomegalovirus humain et methode de production associee
US15/305,494 US20170119874A1 (en) 2014-04-23 2015-04-23 Human cytomegalovirus vaccine compositions and method of producing the same
EP15719409.3A EP3134117A1 (fr) 2014-04-23 2015-04-23 Compositions de vaccin contre le cytomégalovirus humain et méthode de production associée

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2014/001168 WO2015165480A1 (fr) 2014-04-30 2014-04-30 Compositions de vaccin de cytomégalovirus humain et leur procédé de production

Publications (1)

Publication Number Publication Date
WO2015165480A1 true WO2015165480A1 (fr) 2015-11-05

Family

ID=50774827

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2014/001168 WO2015165480A1 (fr) 2014-04-23 2014-04-30 Compositions de vaccin de cytomégalovirus humain et leur procédé de production

Country Status (1)

Country Link
WO (1) WO2015165480A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016067239A1 (fr) * 2014-10-31 2016-05-06 Glaxosmithkline Biologicals Sa Cellules de mammifères exprimant des antigènes du cytomégalovirus
US10064935B2 (en) 2015-10-22 2018-09-04 Modernatx, Inc. Human cytomegalovirus RNA vaccines
JP2019535740A (ja) * 2016-11-22 2019-12-12 クロトー セラピューティクス インコーポレイテッドＫｌｏｔｈｏ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 新規な組換えクロトータンパク質ならびにそれを含む組成物および方法
US10695419B2 (en) 2016-10-21 2020-06-30 Modernatx, Inc. Human cytomegalovirus vaccine
US10815291B2 (en) 2013-09-30 2020-10-27 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994012520A1 (fr) 1992-11-20 1994-06-09 Enzon, Inc. Segment de liaison pour polypeptides fusionnes lies
WO1995014026A1 (fr) 1993-11-17 1995-05-26 Laboratoires Om S.A. Disaccharides de glucosamine, leur procede de preparation, composition pharmaceutique les contenant, et leurs utilisations
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
WO1999064301A1 (fr) 1998-06-08 1999-12-16 Sca Emballage France Emballage a remise a plat rapide
WO2000000462A1 (fr) 1998-06-30 2000-01-06 Om Pharma Nouveaux pseudodipeptides acyles, leur mode de preparation et les compositions pharmaceutiques en renfermant
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
WO2002046227A2 (fr) 2000-12-07 2002-06-13 Eli Lilly And Company Proteines hybrides glp-1
WO2004009823A1 (fr) 2002-07-18 2004-01-29 Lonza Biologics Plc. Technique d'expression de proteines de recombinaison dans des cellules d'ovaire de hamster chinois (cho)
WO2007136778A2 (fr) 2006-05-19 2007-11-29 Teva Pharmaceutical Industries, Ltd. Protéines de fusion, leurs utilisations et leurs procédés de production
WO2012106377A2 (fr) * 2011-01-31 2012-08-09 The Trustees Of The University Of Pennsylvania Molécules d'acide nucléique codant de nouveaux antigènes d'herpès, vaccin les comprenant et procédés pour les utiliser
WO2013006837A1 (fr) * 2011-07-06 2013-01-10 Novartis Ag Emulsions huile dans eau cationiques
WO2014005959A1 (fr) * 2012-07-06 2014-01-09 Novartis Ag Complexes de protéines de cytomégalovirus
WO2014018117A1 (fr) * 2012-07-27 2014-01-30 Diamond Don J Vaccin mva pour l'administration d'un complexe ul128 et la prévention d'une infection par cmv
WO2014068001A1 (fr) * 2012-10-30 2014-05-08 Redbiotec Ag Vaccins recombinants à base de particules contre l'infection par le cytomégalovirus humain

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5525491A (en) 1991-02-27 1996-06-11 Creative Biomolecules, Inc. Serine-rich peptide linkers
WO1994012520A1 (fr) 1992-11-20 1994-06-09 Enzon, Inc. Segment de liaison pour polypeptides fusionnes lies
WO1995014026A1 (fr) 1993-11-17 1995-05-26 Laboratoires Om S.A. Disaccharides de glucosamine, leur procede de preparation, composition pharmaceutique les contenant, et leurs utilisations
WO1999064301A1 (fr) 1998-06-08 1999-12-16 Sca Emballage France Emballage a remise a plat rapide
WO2000000462A1 (fr) 1998-06-30 2000-01-06 Om Pharma Nouveaux pseudodipeptides acyles, leur mode de preparation et les compositions pharmaceutiques en renfermant
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
WO2002046227A2 (fr) 2000-12-07 2002-06-13 Eli Lilly And Company Proteines hybrides glp-1
WO2004009823A1 (fr) 2002-07-18 2004-01-29 Lonza Biologics Plc. Technique d'expression de proteines de recombinaison dans des cellules d'ovaire de hamster chinois (cho)
WO2007136778A2 (fr) 2006-05-19 2007-11-29 Teva Pharmaceutical Industries, Ltd. Protéines de fusion, leurs utilisations et leurs procédés de production
WO2012106377A2 (fr) * 2011-01-31 2012-08-09 The Trustees Of The University Of Pennsylvania Molécules d'acide nucléique codant de nouveaux antigènes d'herpès, vaccin les comprenant et procédés pour les utiliser
WO2013006837A1 (fr) * 2011-07-06 2013-01-10 Novartis Ag Emulsions huile dans eau cationiques
WO2014005959A1 (fr) * 2012-07-06 2014-01-09 Novartis Ag Complexes de protéines de cytomégalovirus
WO2014018117A1 (fr) * 2012-07-27 2014-01-30 Diamond Don J Vaccin mva pour l'administration d'un complexe ul128 et la prévention d'une infection par cmv
WO2014068001A1 (fr) * 2012-10-30 2014-05-08 Redbiotec Ag Vaccins recombinants à base de particules contre l'infection par le cytomégalovirus humain

Non-Patent Citations (28)

* Cited by examiner, † Cited by third party
Title
"Cryopreservation and Freeze-Drying Protocols", 2007, SPRINGER
"Vaccine Adjuvants", 2000, HUMANA PRESS
ALSARRAF ET AL., ACTA CRYSTALLOGR SECT F STRUCT BIOL CRYST COMMUN, vol. 67, 1 October 2011 (2011-10-01), pages 1253 - 1256
ARIZA-HEREDIA ET AL., CANCER LETT, vol. 342, 2014, pages 1 - 8
BEAM ET AL., CURR INFECT DIS REP, vol. 14, 2012, pages 633 - 41
BERENCSI ET AL., J INFECT DIS, vol. 183, 2001, pages 1171 - 9
CHU ET AL., GENE, vol. 13, 1981, pages 197
DAVIS ET AL.: "Basic Methods in Molecular Biology", 1986, ELSEVIER
FU, TM ET AL., VACCINE, vol. 32, no. 22, 7 May 2014 (2014-05-07), pages 2525 - 2533
GOSSEN; BUJARD, PNAS, vol. 89, no. 12, 15 June 1992 (1992-06-15), pages 5547 - 51
GRAHAM ET AL.: "Virology", vol. 52, 1973, pages: 456
GREEN ET AL.: "Molecular Cloning - a laboratory manual", 2012, CSH LABORATORY PRESS
GRESPY ET AL., PLOS ONE, vol. 6, no. 3, 21 March 2011 (2011-03-21), pages E18051
GROSSE ET AL., J CLIN VIROL., vol. 41, no. 2, 2008, pages 57 - 62
HEINEMANN ET AL., THE J. OF INFECTIOUS DISEASE, vol. 193, no. 10, 2006, pages 1350 - 1360
HELDWEIN ET AL., SCIENCE, vol. 313, 2006, pages 217 - 20
KABANOVA A ET AL: "Antibody-driven design of a human cytomegalovirus gHgLpUL128L subunit vaccine that selectively elicits potent neutralizing antibodies", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 111, no. 50, 16 December 2014 (2014-12-16), pages 17965 - 17970, XP055162771, ISSN: 0027-8424, DOI: 10.1073/pnas.1415310111 *
KOTTON, CN, NAT REV NEPHROL, vol. 6, 2010, pages 711 - 721
LILLERI D ET AL: "Fetal Human Cytomegalovirus Transmission Correlates with Delayed Maternal Antibodies to gH/gL/pUL128-130-131 Complex during Primary Infection", PLOS ONE, vol. 8, no. 3, 29 March 2013 (2013-03-29), pages e59863, XP055162781, DOI: 10.1371/journal.pone.0059863 *
MACAGNO ET AL., J VIROL., vol. 84, no. 2, January 2010 (2010-01-01), pages 1005 - 13
MURPHY ET AL., CURR. TOP. MICROBIOL. IMMUNOL., vol. 325, 2008, pages 1 - 19
NEFF ET AL., PROC SOC EXP BIOL MED, vol. 160, 1979, pages 32 - 7
PALMENBERG, A.C. ET AL., VIROLOGY, vol. 190, 1992, pages 754 - 762
PLOTKIN ET AL., J INFECT DIS, vol. 134, 1976, pages 470 - 5
SACCOCCIO ET AL., VACCINE, vol. 29, 2011, pages 2705 - 11
SCHLEISS, FUTURE VIROL., vol. 8, no. 12, 2013, pages 1161 - 1182
WANG ET AL., PROC NATL ACAD SCI USA, vol. 102, 2005, pages 18153 - 8
WATEMBERG ET AL., CLIN PEDIATR (PHILA, vol. 41, no. 7, 2002, pages 519 - 22

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10815291B2 (en) 2013-09-30 2020-10-27 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
BE1023364B1 (fr) * 2014-10-31 2017-02-20 Glaxosmithkline Biologicals S.A. Cellules de mammiferes exprimant des antigenes du cytomegalovirus
BE1023840B1 (fr) * 2014-10-31 2017-08-10 Glaxosmithkline Biologicals S.A. Cellules de mammiferes exprimant des antigenes du cytomegalovirus
BE1023841B1 (fr) * 2014-10-31 2017-08-10 Glaxosmithkline Biologicals S.A. Cellules de mammiferes exprimant des antigenes du cytomegalovirus
US10414802B2 (en) 2014-10-31 2019-09-17 Glaxosmithkline Biologicals S.A. Mammalian cells expressing cytomegalovirus antigens
WO2016067239A1 (fr) * 2014-10-31 2016-05-06 Glaxosmithkline Biologicals Sa Cellules de mammifères exprimant des antigènes du cytomégalovirus
US10064935B2 (en) 2015-10-22 2018-09-04 Modernatx, Inc. Human cytomegalovirus RNA vaccines
US10383937B2 (en) 2015-10-22 2019-08-20 Modernatx, Inc. Human cytomegalovirus RNA vaccines
US11484590B2 (en) 2015-10-22 2022-11-01 Modernatx, Inc. Human cytomegalovirus RNA vaccines
US10716846B2 (en) 2015-10-22 2020-07-21 Modernatx, Inc. Human cytomegalovirus RNA vaccines
US10695419B2 (en) 2016-10-21 2020-06-30 Modernatx, Inc. Human cytomegalovirus vaccine
US11197927B2 (en) 2016-10-21 2021-12-14 Modernatx, Inc. Human cytomegalovirus vaccine
US11541113B2 (en) 2016-10-21 2023-01-03 Modernatx, Inc. Human cytomegalovirus vaccine
JP2019535740A (ja) * 2016-11-22 2019-12-12 クロトー セラピューティクス インコーポレイテッドＫｌｏｔｈｏ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 新規な組換えクロトータンパク質ならびにそれを含む組成物および方法
JP7244923B2 (ja) 2016-11-22 2023-03-23 クロトー セラピューティクス インコーポレイテッド 新規な組換えクロトータンパク質ならびにそれを含む組成物
US11406703B2 (en) 2020-08-25 2022-08-09 Modernatx, Inc. Human cytomegalovirus vaccine

Similar Documents

Publication Publication Date Title
US20230265127A1 (en) Stabilized soluble pre-fusion rsv f polypeptides
JP7238000B2 (ja) 安定化された可溶性融合前ｒｓｖ ｆポリペプチド
DK2445526T3 (en) Recombinant RSV antigens.
ES2858315T3 (es) Proteína F de prefusión de VRS soluble estabilizada para uso en la profilaxis de la infección por VRS
JP6679484B2 (ja) ヒトヘルペスウイルス三量体糖タンパク質Ｂ、三量体ｇＢを含むタンパク質複合体、及びワクチンとしてのそれらの使用
WO2015165480A1 (fr) Compositions de vaccin de cytomégalovirus humain et leur procédé de production
US20170119874A1 (en) Human cytomegalovirus vaccine compositions and method of producing the same
JP6735269B2 (ja) インフルエンザウイルスワクチンおよびその使用
EP3758747A1 (fr) Vaccins à base de nanostructures auto-assemblables
JP2023533772A (ja) ＳＡＲＳ－ＣｏＶ－２及びインフルエンザ混合ワクチン
ES2836598T3 (es) Proteínas F de RSV prefusión estabilizadas
EP2614072A2 (fr) Vaccin à cytomégalovirus humain
WO2019092002A1 (fr) Compositions pharmaceutiques pour le traitement ou la prévention des infections virales
JP2020515522A (ja) 免疫応答を誘導するヘルペスウイルスエンベロープタンパク質の組み合わせのワクチン組成物
JP7146926B2 (ja) Ｃｄ４ヘルパーｔ細胞エピトープの融合ペプチドおよびそのワクチン
KR101832610B1 (ko) 돼지 유행성 설사 바이러스 유래 수용성 재조합 항원 단백질 및 이를 포함하는 돼지 유행성 설사 예방 또는 치료용 백신 조성물
TW202206598A (zh) 對抗ＳＡＲＳ－ＣｏＶ－２之疫苗及其製品
US20230265128A1 (en) Stabilised viral fusion proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14725909

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14725909

Country of ref document: EP

Kind code of ref document: A1